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1  Summary 
The peroxisome proliferator activated receptor γ (PPARγ) plays an eminent role during 
alternative  activation  of  macrophages  and  resolution  of  inflammation.  As  an  anti-
inflammatory signaling molecule, it seems likely that it is tightly regulated dependent 
on  the  state  of  the  immune  response.  There  is  growing  evidence  that  PPARγ 
expression  is  reduced  during  inflammation,  whereas  molecular  mechanisms  are  ill-
defined.  Even  though,  its  role  in  immunosuppression  is  getting  more  definite. 
Apoptotic cells (AC) provoke an active repression of pro-inflammatory responses inter 
alia  by  the  inhibition  of  pro-inflammatory  cytokine  expression  or  attenuated 
generation  of  reactive  oxygen  species  (ROS).  The  reduced  formation  of  ROS  was 
attributed  to  PPARγ  activation,  while  mechanisms  behind  the  reduced  cytokine 
expression remained unclear. Therefore, my Ph.D. thesis addressed the role of PPARγ 
during inhibited cytokine synthesis in response to  AC and the regulation of PPARγ 
expression during an inflammatory response, which was initiated by lipopolysaccharide 
(LPS) exposure.  
In the first part of the thesis, I investigated the role of PPARγ in coordinating the 
attenuation  of  pro-inflammatory  cytokine  expression  in  response  to  AC.  Exposing 
murine  RAW264.7  macrophages  to  AC  prior  to  LPS-stimulation,  reduced  NFκB 
transactivation and lowered target gene expression of e.g. TNFα and IL-6 compared to 
controls. In macrophages over-expressing a dominant negative (d/n) mutant of PPARγ, 
NFκB transactivation in response to LPS was restored, while using macrophages from 
myeloid  lineage-specific  conditional  PPARγ  knock-out  mice  proved  that  PPARγ 
transmitted the anti-inflammatory response delivered by AC. Domain analysis revealed 
that  amino  acids  32-250  are  essential  for  inhibition  of  NFκB.  Mutation  of  a 
SUMOylation (SUMO: small-ubiquitin related modifier) site in this region (K77R) and 
interfering SUMOylation by silencing the SUMO E3 ligase PIAS1 (protein inhibitor of 
activated  Stat1)  eliminated  AC-provoked  NFκB  inhibition  and  concomitant  TNFα 
expression. Chromatin-immunoprecipitation assays demonstrated that AC prevented 
the  LPS-induced  removal  of  nuclear  receptor  co-repressor  (NCoR)  from  the  κB 
response  element  within  the  TNFα  promoter.  I  concluded  that  AC  induce  PPARγ 
SUMOylation to attenuate the removal of NCoR, thereby blocking transactivation of Summary    2 
NFκB.  This  contributes  to  an  anti-inflammatory  phenotype  shift  in  macrophages  in 
response to AC, by lowering pro-inflammatory cytokine production.  
The  second  part  addressed  molecular  mechanisms  responsible  for  reduced  PPARγ 
expression upon LPS exposure. PPARγ gained considerable interest as a therapeutic 
target during chronic inflammatory diseases. Remarkably, the pathogenesis of diseases 
such as multiple sclerosis or Alzheimer’s disease is associated with impaired PPARγ 
expression.  Initiation  of  an  inflammatory  response  by  exposing  primary  human 
macrophages to LPS revealed a rapid decline of PPARγ1 expression. PPARγ1 mRNA 
decrease was prevented by inhibition of NFκB and also after pre-treatment with the 
PPARγ agonist rosiglitazone, suggesting a NFκB-dependent pathway, because activated 
PPARγ is known to inhibit NFκB transactivation. Since promoter activities were not 
affected by LPS, I focused on mRNA stability and noticed a decreased PPARγ1 mRNA 
half-life. RNA stability is often regulated via 3’ untranslated regions (UTRs). Therefore, I 
analyzed the impact of the PPARγ-3’UTR by luciferase assays. LPS significantly reduced 
luciferase activity of pGL3-PPARγ-3’UTR, suggesting that PPARγ1 mRNA is destabilized. 
Deletion of a potential miR-27a/b binding site within the 3’UTR completely restored 
luciferase  activity.  Moreover,  inhibition  of  miR-27b,  which  was  induced  upon  LPS-
exposure,  partially  reversed  PPARγ1  mRNA  decay,  whereas  the  mature  miR-27 
mimicked  the  effect  of  LPS.  MiR-27b  was  at  least  partially  induced  by  NFκB,  thus 
correlating with NFκB-dependent PPARγ1 mRNA decrease. Since deletion of the miR-
27 site also containing an AU-rich element (ARE) completely abrogated LPS-induced 
reduction but inhibition of miR-27b only partially restored PPARγ1 mRNA expression, I 
suggested an additional implication of an ARE-binding protein. 
I provide evidence that LPS induces miR-27b, which in turn destabilizes PPARγ1 mRNA. 
Understanding the molecular mechanism of PPARγ mRNA destabilization, might help 
to rationalize inflammatory diseases associated with impaired PPARγ expression. Even 
though, further experiments are needed to clarify the potential involvement of ARE-
binding proteins.  
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2  Zusammenfassung 
Chronische Entzündungskrankheiten entstehen häufig in Folge einer unkontrollierten 
Entzündungsreaktion und damit verbundenen irreversiblen Schäden des umliegenden 
Gewebes.  Die  Ausbildung  eines  anti-inflammatorischen  Makrophagen-Phänotyps  ist 
ein  wichtiger  Bestandteil  zur  Beendigung  von  Entzündungen.  Charakteristisch  für 
diesen  Phänotyp  ist  eine  verminderte  Synthese  pro-inflammatorischer  Zytokine, 
welche  teilweise  auf  die  Aktivierung  des  Transkriptionsfaktors  PPARγ  (‚peroxisome 
proliferator  activated  receptor  γ‘)  zurückzuführen  ist.  Daher  ist  die  Regulation  der 
Aktivierung als auch der Expression von PPARγ entscheidend für die Immunantwort 
von Makrophagen.  
Es konnte bereits gezeigt werden, dass durch die Phagozytose apoptotischer Zellen 
(AZ) zum einen PPARγ aktiviert und zum anderen die Zytokinexpression durch eine 
Hemmung von NFκB (‚nuclear factor κB‘) vermindert wird. Daher untersuchte ich im 
ersten  Teil  meiner  Arbeit  die  Rolle  von  PPARγ  bei  der  Inhibition  von  NFκB  nach 
Interaktion  mit  AZ.  Die  Stimulation  von  RAW264.7-Makrophagen  mit  AZ  führte  zu 
einer  Hemmung  der  NFκB-Aktivität,  welche  durch  Überexpression  einer  dominant-
negativen Mutante von PPARγ reduziert war. Weiterhin konnte in primären PPARγ-
knock-out Makrophagen keine Hemmung der TNFα-Expression, als klassisches NFκB-
Zielgen, festgestellt werden. Analysen der PPARγ-Protein Domänen zeigten, dass die 
Aminosäuren 32-250 essentiell für die NFκB-Inhibition sind. Mutation der in diesem 
Bereich  liegenden  SUMOylierungsstelle  K77  (SUMO:  „small-ubiquitin  related 
modifier“) als auch das Ausschalten der essentiellen SUMO-E3-Ligase PIAS1 („protein 
inhibitor of activated Stat1“) verhinderte die Hemmung von NFκB und bestätigte die 
SUMOylierung von PPARγ als zugrunde liegenden Mechanismus. Als verantwortlichen 
Repressor  identifizierte  ich  NCoR  („nuclear  receptor  co-repressor“),  welcher  im 
Ruhezustand  konstitutiv  an  NFκB-Bindestellen  verschiedener  pro-inflammatorischer 
Promotoren  gebunden  ist.  Nach  TLR4-Aktivierung  dissoziiert  dieser  von  der 
Promotorregion und wird abgebaut. Durch Chromatin-Immunpräzipitationen konnte 
ich  zeigen,  dass  vermutlich  SUMOyliertes  PPARγ  nach  Interaktion  mit  AZ  die 
Dissoziation von NCoR und damit die Zielgen-Expression verhindert. Die Aufklärung 
dieses Mechanismus trägt damit zum weiteren Verständnis bei, wie AZ einen anti-Zusammenfassung    4 
inflammatorischen Makrophagen-Phänotyp hervorrufen und damit zur Eindämmung 
einer Entzündungsreaktion beitragen.  
Bei  verschiedenen  Entzündungskrankheiten  wie  Alzheimer  oder  auch  Multipler 
Sklerose konnte eine Verringerung der PPARγ-Expression nachgewiesen werden. Da 
der Mechanismus dieser Reduktion jedoch weitgehend unbekannt ist, beschäftigte ich 
mich  im  zweiten  Teil  meiner  Arbeit  mit  der  Expressionsregulation  von  PPARγ  in 
Makrophagen.  Die  Stimulation  von  primären  humanen  Makrophagen  mit  LPS 
verringerte  den  PPARγ1  mRNA-Gehalt.  Diese  mRNA-Reduktion  konnte  durch 
Hemmung  von  NFκB  als  auch  durch  Vorstimulation  mit  dem  PPARγ-Agonisten 
Rosiglitazone  verhindert  werden,  was  auf  einen  NFκB-abhängigen  Mechanismus 
hinwies. Durch Promotor-Reporteranalysen konnte eine Reduktion der PPARγ1 mRNA 
auf  transkriptioneller  Ebene  ausgeschlossen  werden.  LPS  führte  vielmehr  zu  einer 
3‘-UTR  (‚untranslated  region‘)-abhängigen  Destabilisierung  der  PPARγ1  mRNA. 
Aufgrund einer potentiellen Bindestelle für microRNA-27a/b (miR-27a/b), untersuchte 
ich deren Expression. LPS führte - zum Teil NFκB abhängig - zur Induktion von miR-27a 
und b. Eine Depletion der miR-27 Bindestelle innerhalb der PPARγ-3’UTR verhinderte 
vollständig den destabilisierenden Effekt von LPS. Weiterhin führte die Inhibition von 
miR-27b,  nicht  aber  von  miR-27a,  zur  teilweisen  Aufhebung  der  LPS-induzierten 
Reduktion. Die Destabilisierung von PPARγ konnte außerdem durch Transfektion mit 
miR-27b simuliert werden, wobei die additive Zugabe von LPS den Effekt nur wenig 
verstärkte.  
Meine Daten beweisen, dass LPS-induzierte miR-27b zur Destabilisierung der PPARγ1 
mRNA führt. Die Aufklärung des vorliegenden molekularen Mechanismus könnte dazu 
beitragen,  das  Verständnis  und  damit  verbundene  Behandlungsmethoden  von 
Entzündungskrankheiten,  welche  eine  reduzierte  PPARγ-Expression  zeigen,  zu 
erweitern. Introduction    5 
3  Introduction 
3.1  Regulation of gene expression 
Gene  expression  depicts  a  complex process  where the  information from  a  gene  is 
translated in a gene product, most often a protein but also non-coding ribonucleic 
acids (RNAs) like ribosomal or micro RNAs (miRNAs or miRs). This complex machinery 
enables cells or organisms to accomplish the challenge of life, i.e. simple survival by 
regulating  energy  supply  and  metabolism,  but  also  proliferation,  differentiation  or 
adaption to  environmental  changes  such  as  infection  or  injury.  Gene expression  is 
controlled at different levels including transcription, RNA splicing, post-transcriptional 
regulation,  translation  and  post-translational  modifications.  In  the  following 
paragraphs  I  briefly  introduce  regulation  at  transcriptional  and  post-transcriptional 
level.  
3.1.1  Transcription 
Transcription describes the synthesis of messenger RNA (mRNA) under the direction of 
a deoxyribonucleic acid (DNA) sequence. RNA is generated by the RNA polymerase II, 
which  requires  a  core promoter  essential  for binding  of  the  pre-initiation  complex 
recognizing the so called TATA-box. Only a small, basal subset of genes is transcribed 
by  this  pre-initiation  complex,  whereas  initiation  of  transcription  mostly  requires 
transcription  factors.  These  proteins  facilitate  a  coordinated  induction  of  genes 
dependent on environmental changes, often along with co-activators or co-repressors. 
Transcription  factors  bind  to  specific  DNA  consensus  sequences  within  promoter 
regions  assisting  or  blocking  the  recruitment  of  the  RNA  polymerase  complex. 
Initiation by transcription factors often needs the help of co-regulators, which bind to 
transcription factors. They facilitate recruitment or control accessibility of DNA to the 
RNA polymerase complex (1, 2). 
Unlike prokaryotic DNA, eukaryotic DNA is packed in a highly organized structure. The 
double helix is wound around histone proteins, while again 8 histone/DNA complexes 
form a nucleosome, building a 10 nm-fiber, the so called ‘beads-on-a-string’. These 
fibers  are  packed  with  the  help  of  Histone  1  to  a  complex  chromatin  structure. 
Chromatin structure strongly influences gene transcription simply by the accessibility Introduction    6 
of DNA to transcription factors and the RNA polymerase complex. Thus, chromatin 
forms  the  first  barrier  for  gene  transcription  and  can  be  modified  by  altering  the 
acetylation  status  of  histones.  This  is  accomplished  among  others  by  histone 
acetyltransferases  (HATs)  and  histone  deacetylases  (HDACs).  Histones  are  normally 
positively  charged  and  therewith  bind  to  the  negatively  charged  DNA  thereby 
decreasing  accessibility.  Acetylation  by  HATs  changes  amines  to  amides  thus 
neutralizing positive charges and expanding chromatin. Subsequently, the transcription 
machinery is able to bind and initiate gene expression. HDACs remove acetyl groups 
and thereby increase positive charges, which concomitantly prevents transcription. Co-
activators and co-repressor often exhibit an intrinsic HAT or HDAC activity or they 
recruit  HATs  or  HDACs  to  achieve  their  function  (1,  2).  Two  well  established  co-
activators  with  intrinsic  HAT  activity  are  cAMP  response  element  (CREB)-binding 
protein (CBP), participating in the activity of hundreds of transcription factors including 
nuclear factor κB (NFκB) and activation protein-1 (AP-1) (3). 
3.1.2  Post-transcriptional regulation 
Besides  transcription,  gene  expression  is  also  controlled  by  post-transcriptional 
regulation, i.e. by altering mRNA stability. In mammalian cells, mRNA half-life ranges 
from  several  minutes to  days,  suggesting  tightly  controlled  and  specific  regulation. 
Altering mRNA half-life enables cells to rapidly react to environmental changes and is a 
common feature during immune responses. In most cases cis-acting elements within 3’ 
untranslated  regions  (UTRs)  are  targeted  by  trans-acting  RNA-binding  proteins 
facilitating mRNA degradation (4). Moreover miRNAs, a new class of small non-coding 
RNAs  have  been  identified  as  trans-acting  molecules,  also  binding  to  cis-acting 
elements within the 3’UTR, mediating rapid mRNA decay or inhibiting translation (5).  
3.1.2.1  ARE-binding proteins 
Trans-acting  RNA-binding  proteins  targeting  mRNA  for  degradation  mostly  interact 
with AU-rich elements (AREs) within the 3’UTR of an individual transcript. AREs have 
first  been  described  for  various  cytokine  transcripts.  Thus,  the  first  ARE-mediated 
mRNA decay was identified by Shaw and Kamen, who inserted the ARE of GM-CSF 
(granulocyte-macrophage-colony stimulating factor) transcript into the 3’UTR of a β-
globin reporter construct and observed rapid degradation of the β-globin mRNA (6). Introduction    7 
Contrarily, deleting the 3’UTR of TNFα (tumor necrosis factor α) or Interleukin (IL) -3 
enhanced  mRNA  stability  and  therewith  gene  expression  (7,  8).  Besides  targeting 
mRNAs  for  their  degradation,  ARE-binding  proteins  can  also  affect  translation 
efficiency.  They  were  originally  believed  to  require  several  copies  of  an  AUUUA 
pentamer,  whereas  also  AU-rich  sequences  can  be  target  for  cis-trans-interactions. 
AREs have been recently categorized into four classes (‘W’ stands for ‘U’ or ‘A’): ARE1: 
AUUUA, ARE2: UUAUUUAWW, ARE3: WWWUAUUUAUWWW, and ARE4: 12-mer A/U 
with maximal one mismatch (9). Degradation of RNAs is in general achieved by the 
removal  of  the  poly  (A)-tail  and  following  exonucleolytic  decay  in  5’-3’  or  3’-5’ 
direction. In 3’ – 5’ direction, mRNA is degraded by the exosome, which is suggested to 
occur during ARE-mediated mRNA decay (10). 
A broad range of ARE-binding proteins with regulatory functions are known so far. One 
of  the  best  described  ARE-binding  proteins  is  tristetraprolin  (TTP),  which  is 
predominantly expressed in macrophages and T-cells. Studies of TTP deficient mice 
showed inflammatory symptoms due to enhanced stability of TNFα, GM-CSF and IL-2 
mRNA (11). Besides TTP, also AUF1 (AU-binding factor 1), Brf1/2 (B-related factor 1/2) 
and KSRP (KH-type splicing regulatory protein) are described to destabilize, whereas 
HuR (human antigen R) rather stabilizes mRNAs. The combination of stabilizing and 
destabilizing factors enables the cell to coordinate a specific and adapted (immune) 
response. For instance, iNOS (inducible nitric oxide synthase) mRNA is destabilized by 
TTP and also KSRP, whereas HuR stabilizes the iNOS transcript, the latter ones both 
competing  for  the  same  ARE  site.  Thus,  dependent  on  the  microenvironment, 
macrophage  iNOS  mRNA  is  degraded  or  stabilized.  Moreover,  also  ARE-binding 
proteins and miRNAs can act in concert, as it was first described for miR-16 and TTP. 
Jing et al. observed that miR-16-mediated TNFα mRNA decay also requires TTP, both 
sharing the ARE ‘AUUUAUAA’. TTP did not directly bind to miR-16, but associated with 
Argonaute (Ago) family members and assists in targeting mRNA (12). 
3.1.2.2  MicroRNAs 
MiRNAs present a large family of small non-coding RNAs with a length of about ~22 
nucleotides. They are transcribed as primary miRNAs (pri-miRNA), which then undergo 
a  two-step  processing.  First,  the  pri-miRNA  is  cleaved  by  the  double-strand 
endonuclease Drosha generating the precursor miRNA (pre-miRNA), which is exported Introduction 
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catabolite repressor factor 4:negative on-TATA-less) deadenylase complex, decapping 
enzymes and activators and following exosomal degradation (reviewed in (15)) (Figure 
3.1).  Even  though  the  decay  is  believed  to  occur  in  so  called  P-bodies  (cellular 
structures enriched with mRNA catabolising enzymes), it was recently demonstrated 
that P-body localization is not required for transcript silencing. However, localization is 
mediated  by  the  P-body  component  GW182,  which  interacts  with  Ago1,  marking 
mRNA  for  degradation.  Mutation  of  GW182  and  Ago1  revealed  that  interaction  is 
essential for mRNA degradation, showing the importance of the C-terminal region of 
GW182 for mRNA decay (16). Moreover, depletion of Ago1 and also GW182 led to an 
up-regulation of many transcripts, underlining their crucial role in miRNA-mediated 
mRNA degradation (17).  
MiRNAs play an eminent role during development and function of immune cells and 
are associated with several inflammatory diseases (18). MiR-155 and miR-146 gained 
special interest and are both induced upon various pro-inflammatory stimuli such as 
the toll-like receptor 4 (TLR4)-ligand lipopolysaccharide (LPS), IL-1 or TNFα (19). MiR-
146 is induced in a NFκB-dependent manner and negatively regulates TLR-signaling via 
repression  of  IRAK1  (IL-1  receptor-associated  kinase  1)  and  TRAF6  (TNF-receptor-
associated factor 6) (19). However, TLR4 activation also triggers induction of miRNAs 
such as miR-21 or miR-132 (18). In contrast, miR-125b, which targets TNFα for post-
transcriptional repression, is reduced upon LPS exposure facilitating a proper TNFα 
production  (20).  Many  miRNAs  have  been  associated  with  cancer,  whereas  more 
recently, the role of miRNAs during chronic inflammation has been investigated. The 
first  evidence  for  an  involvement  of  miRNAs  in  inflammatory  diseases  came  from 
Sonkoly  et  al..  Microarray  analysis  of  patients with  psoriasis,  an  inflammatory  skin 
disorder, revealed among others elevated expression of miR-146, suggesting failure in 
TNFα signaling pathways (21). In rheumatoid arthritis (RA) miR-146a and miR-155 were 
up-regulated in comparison to healthy individuals or patients with osteoarthritis. It 
was proposed that miR-155 might control expression of matrix metalloproteinase-1 
(MMP-1)  and  -3  in  synovial  fibroblasts,  both  enzymes  capable  of  degrading 
extracellular matrix proteins and are involved in the pathogenesis of RA (22, 23). Still, 
the  identification  of  miRNA  functions  in  inflammatory  diseases  needs  further 
investigation.  Introduction    10 
3.2  Inflammation and macrophages 
Inflammation is a complex biological response to noxious conditions such as infection 
or injury and is characterized by its cardinal signs rubor (redness), calor (heat), tumor 
(swelling), dolor (pain) and functio laesa (loss of function), the first four being already 
described in the first century, a. D..  
The innate immune system, consisting mainly of epithelial barrier, phagocytes, natural 
killer cells and the complement system, provides the early lines of defense against 
pathogens. After breaching the epithelial barrier, invading microbes are recognized by 
neutrophils  and  macrophages  via  structures  that  are  characteristic  for  microbial 
pathogens (pathogen-associated molecular pattern (PAMP)). Identification of PAMPs 
enables cells to distinguish self from non-self. PAMPs such as LPS or double-stranded 
RNA  are  in  general  sensed  by  pattern  recognition  receptors  such  as  TLRs.  After 
recognition, macrophages secret cytokines, e.g. IL-1 and TNFα, which in turn stimulate 
endothelial cells to recruit further leukocytes. Thus, inflammation is accompanied by 
rapid  influx  of  neutrophils  and  monocytes  that  differentiate  into  macrophages 
following  migration  into  the  inflamed  tissue.  After  recognition  of  pathogens, 
macrophages and also neutrophils ingest microbes, which are then killed in part by 
reactive  oxygen  species  (ROS)  or  nitric  oxide  (NO)  produced  by  the  phagocytes. 
Activated macrophages furthermore release a variety of inflammatory mediators such 
as  chemokines  and  cytokines  to  attract  other  leukocytes  to  the  site  of  infection. 
Macrophages  also  recruit  and  subsequently  activate  lymphocytes  by  antigen-
presentation, thereby linking the innate and adaptive immune system. Activated B- 
and  T-cells  themselves  enhance  antimicrobial  activities  of  macrophages,  e.g.  by 
secreting  interferon  γ  (IFNγ),  but  also  fight  against  different  types  of  microbes  by 
marking pathogens for elimination or by killing infected cells to abolish reservoirs of 
infection (24).  
Besides building the first line of defense and activating lymphocytes, macrophages are 
also important for the resolution of inflammation and wound healing. Thus, exhibiting 
various functions also suggest various macrophage phenotypes.  
3.2.1  Distinct macrophage phenotypes 
Since Mackaness et al. first described classically activated macrophages in the 1960s as 
major  immune  effector  cells  (25),  considerable  knowledge  was  gained  concerning Introduction    11 
distinct macrophage phenotypes with diverse functional roles. Prevailing views display 
a remarkable plasticity of macrophages with diverse phenotypes and functions that are 
classified towards two extremes: M1 and M2 macrophages.  
The term classical activated macrophage (or M1) defines a phenotype produced in 
response to infection or injury. It is characterized by a high bactericidal competence 
i.e. the production of ROS, NO as well as pro-inflammatory cytokines such as TNFα and 
IL-1β, IL-6 and IL-12, partly accomplished by activation of NFκB (26).  
M2  macrophages  alone  comprise  a  broad  spectrum  of  phenotypes  with  different 
biochemistry and function. To appreciate the functional repertoire of macrophages, 
taking  into  consideration  the  reports  on  intermediate  or  hybrid  activation  states, 
Mosser and Edwards avoided the term M2 macrophages and used the operatively 
useful  discrimination  between  regulatory  and  wound-healing  macrophages, 
considering their implication in immune regulation and wound healing (27). Originally, 
IL-4 and IL-13 were described as alternative activators of macrophages, characterized 
by attenuating the production of pro-inflammatory mediators, i.e. pro-inflammatory 
cytokines, NO and ROS. At the same time alternative macrophage activation enhances 
the  expression  of  IL-10,  arginase  1/2  and  the  mannose  receptor  (MR).  This 
macrophage phenotype was classified as a M2a phenotype (28) or more recently as 
wound-healing  macrophages.  The  latter  nomenclature  refers  to  the  secretion  of 
extracellular matrix components, thus fostering wound-healing (27).  
Regulatory or M2c macrophages are generated by environmental stimuli such as IL-10, 
glucocorticoids,  prostaglandins  and  also  apoptotic  cells  (AC).  Compared  to  wound-
healing macrophages they do not produce extracellular matrix, rather secreting high 
levels  of  IL-10  and  transforming  growth  factor  β  (TGFβ),  and  thus  showing  a 
pronounced  immune  regulatory  function.  M2b  macrophages  also  exert 
immunoregulatory  functions  and  are  generated  by  combined  exposure  to  immune 
complexes (by Fc γ receptor binding) and TLR or IL-1 receptor ligands. Similar to M2a 
and M2c, they show increased IL-10 levels, reduced IL-12 secretion but still produce 
low levels of pro-inflammatory cytokines such as TNF, IL-6 and IL-1. Because of their 
strong  induction  of  Th2  responses,  they  were  originally  determined  as  type  II 
macrophages (27, 29). Introduction    12 
Even though these classifications tend to specifically describe macrophage subtypes, 
they still display only extremes of a continuum, especially considering that hybrid-type 
cells exist (extensively reviewed in (27, 28)).  
3.2.2  NFκB 
The NFκB/Rel family of transcription factors plays a crucial role in the coordination of 
both  innate  and  adaptive  immune  responses.  Thus,  in  macrophages  as  well  as  in 
lymphocytes, NFκB is activated upon a wide variety of stimuli including pathogens, 
pro-inflammatory  cytokines  such  TNFα  or  IL-1  and  also  activation  of  the  T-  and 
accordingly B-cell receptors.  
The NFκB family consists of five members: p65 (RelA), p50, p52, c-Rel and RelB, which 
can form homodimers or heterodimers with each other. The transcription activation 
domain is only present in p65, c-Rel and RelB, hence the homodimer p50/p50 acts as a 
transcriptional  repressor,  while  binding  to  DNA  but  not  transactivating.  The  main 
activated form of NFκB is the p65/p50 homodimer. In its inactivated state, cytosolic 
NFκB is associated to IκB (inhibitor of NFκB), preventing its translocalization to the 
nucleus and subsequent transactivation. Upon several stimuli, IKKα and β (IκB kinases 
α/β)  are  activated,  in  turn  phosphorylating  IκB,  which  is  then  ubiquitinated  and 
degraded by the proteasome. Dissociation from IκB initiates translocalization of NFκB 
to the nucleus followed by binding to specific site within promoters of its target genes 
(κB-response element (κB-RE)) (reviewed in(30)). 
Since  I  predominantly  used  LPS  to  initiate  inflammation,  I  further  introduce  TLR4-
dependent NFκB transactivation. LPS ligation to the TLR4:CD14:MD2 (TLR4:cluster of 
differentiation 14:myeloid differentiation 2) complex leads to association of MyD88 
and IRAK, which in turn recruits and phosphorylates TRAF6. TRAF6 triggers activation 
of  the  TAB2  (TAK1-binding  protein  2)-TAK1  (TGFβ-activated  kinase  1)-TAB1  (TAK1-
binding  protein  1)  complex  in  turn  activating  the  IKK  complex  and  following 
transactivation (Figure 3.2).  
Activated NFκB induces the transcription of chemokines, cytokines, stress-response 
proteins and also enzymes with high bactericidal competence such as components of 
the  NADPH  oxidase  complex  or  iNOS.  Gene  knock-out  studies  underscored  the 
importance of NFκB and indicated distinct roles for the regulation of the innate and 
adaptive  immunity.  Lack  of  the  p65  subunit  is  embryonically  lethal  due  to  liver Introduction 
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with resolution of inflammation and wound repair, whereas both are predominantly 
mediated by macrophages. Mechanisms of dampening inflammation have long been 
elusive,  while  emerging  evidence  now  suggests  an  active  coordinated  program. 
Apoptosis  of  leukocytes  especially  of  neutrophils  and  concomitant  clearance  by 
phagocytes is a relevant event during resolution. As described below, phagocytosis of 
AC by itself exhibits a shift towards an anti-inflammatory phenotype of macrophages 
(32). As switching off inflammation is an intrinsic feature of inflammation, the pro-
inflammatory  prostaglandins  (PG)  E2  and  D2  trigger  the  generation  of  lipoxins  and 
resolvins, in turn repressing cytokine expression and stimulating engulfment of AC. 
Moreover, anti-inflammatory cytokines such as IL-10 or TGFβ are also induced during 
the  initial  phase  of  an  immune  response,  again  suppressing  inflammation  by  e.g. 
negatively regulating TLR signaling (33, 34).  
Beside IL-10 and TGFβ, peroxisome proliferator-activated receptor γ (PPARγ) has been 
implicated in macrophage polarization towards an anti-inflammatory phenotype and 
therewith contributes to resolution of inflammation.  
3.3  Peroxisome proliferator–activated receptor γ (PPARγ) 
PPARs belong to the nuclear receptor superfamily of ligand-dependent transcription 
factors. There are three isoforms described: α, γ and δ. PPARα was described in 1990 
as  a  factor  responding  to  several  compounds  inducing  peroxisome  proliferation  in 
rodents,  where  this  subfamily  was  named  after  (35).  Indeed,  PPARα  mediates 
peroxisome  proliferation,  whereas  this  function  is  not  shared  by  the  other  two 
isoforms. PPARγ was first identified as a crucial regulator of adipogenesis and glucose 
metabolism, whereas it later also emerges as an anti-inflammatory mediator.  
3.3.1  Structure  
As nearly all nuclear receptors, PPARγ can be divided into four domains (Figure 3.3). 
The C-terminal ligand-binding domain (LBD) containing the activation function 2 (AF2), 
is required for ligand-binding and dimerization with retinoid X receptors (RXRs). Beside 
a hinge and a DNA binding domain (DBD), PPARγ also contains the so called activation 
function  1  (AF1).  This  region  has  ligand-independent  transcriptional  activity  (36), 
whereas deletion of the N-termini also showed inhibitory effects on ligand-dependent 
transactivation, which was due to phosphorylation of S82 (112 in PPARγ2) by members Introduction 
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levels in rodents. One year later, it was found that TZDs are direct ligands for PPARγ 
(49), resulting in an improved insulin sensitivity and concomitant reduction of glucose 
levels  (reviewed  in  (50)).  Two  prominent  TZDs  are  pioglitazone  and  rosiglitazone, 
which are in widespread use for the treatment of type-2 diabetes mellitus.  
The role of PPARγ during adipogenesis and glucose metabolism predominantly relies 
on PPARγ-dependent gene induction of e.g. adipocyte protein 2, CD36, lipoprotein 
lipase or glucose transporter 4 (50). Gene induction requires transactivation by ligand-
binding and heterodimerization with the ligand-dependent transcription factor RXR, 
which also belongs to the nuclear hormone receptors. PPARγ-ligand binding is not 
essential for interaction with RXR. However, under basal conditions PPARγ is halted in 
an  inactive  state  by  the  co-repressor  complex  NCoR/SMRT  (nuclear  receptor  co-
repressor/silencing mediator of retinoid and thyroid hormone) (51, 52). Ligand binding 
triggers conformational changes or stabilizes dynamical changes which in turn initiate 
dissociation  of  NCoR/SMRT  and  favour  co-activator  recruitment  of  e.g.  steroid 
receptor co-activator-1 (Src-1) and CBP/p300 (53).  
3.3.3  Anti-inflammatory properties 
Beside regulation of adipogenesis and glucose metabolism, PPARγ is well described for 
its anti-inflammatory properties in T-, B-cells, monocytes, and macrophages. During 
differentiation of monocytes into macrophages PPARγ is strongly induced mostly via 
the promoter 3 but also via promoter 1 (54), whereas it seems not to be required for 
differentiation (55, 56).  
Immunosuppressive  action  of  PPARγ  results  either  from  the  induction  of  anti-
inflammatory  or  the  inhibition  of  pro-inflammatory  mediators.  Especially  in 
alternatively activated macrophages, IL-4 induced expression of arginase 1 and the 
mannose receptor was eliminated in macrophages from macrophage-specific PPARγ 
knock-out mice (57). IL-4 activates PPARγ by induction of the 15-lipoxygenase which in 
turn generates the ligands 13-HODE and 15-HETE through metabolizing arachidonic 
and linoleic acid (58). Moreover, Odegaard et al. gave evidence that the reduced IL-6 
expression in response to IL-4 is also PPARγ-dependent. Furthermore, activated PPARγ 
represses the expression of TNFα, IL-1β, IL-12, MMP-9 and iNOS (59), whereas several 
mechanisms of transrepression are described (Figure 3.4 A-E):  
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intermediary factor 2’, ‘amplified in breast cancer-1’ and ‘thyroid hormone receptor-
associated  protein  220  subunit’/’vitamin  D  receptor-interacting
  protein  205`  in  a 
ligand-type specific manner (Figure 3.4 A) (62). 
(B) Direct interaction with transcription factors  
Several  reports  suggested  that  PPARγ/RXR  heterodimers  inhibit  expression  of  pro-
inflammatory cytokines by direct binding of transcription factors and therewith repress 
activity of NFκB, signal transducer and activator of transcription 1 (STAT1) or AP-1 
(Figure  3.4  B)  (reviewed  in  (63)).  OxLDL,  which  is  well  known  to  activate  PPARγ, 
reduces  LPS-induced  IL-12p40  expression  in  macrophages  by  inhibiting  NFκB 
transactivation. GST-pull down assays revealed that PPARγ directly binds to p65 and to 
a lower extent to p50, whereas the interaction was independent of ligand-binding and 
RXR (64). Moreover, immunoprecipitation of nuclear factor of activated T-cells (NFAT) 
revealed that inhibition of NFAT in human peripheral blood T lymphocytes is also due 
to direct binding by PPARγ, resulting in a reduced IL-2 expression (65). 
(C) Inhibition of the MAP kinase cascade 
MAPKs  are  serine/threonine-specific  kinases  which  respond  to  extracellular  stimuli 
(mitogens)  and  regulate  various  cellular  processes  such  as  proliferation, 
differentiation,  apoptosis  and  inflammation.  Beside  the  classical  MAPK  Erk1/2 
(extracellular signal-regulated kinase), a lot of others have been identified such as p38 
or Jnk (c-jun N-terminal kinase). The latter ones are also known as stress-activated 
protein kinases. In general, the MAPK cascade includes several kinases activating each 
other and results in the transactivation of transcription factors (66).  
PPARγ was found to control the cascade at different levels. In the colon, PPARγ ligands 
reduced activity of the Jnk and p38 MAPK resulting in a decrease of TNFα and IL-1β 
production  (67).  Furthermore,  inhibition  of  LPS-induced  p38  phosphorylation  by 
pioglitazone was recently observed in microglia-enriched cultures (68). Goetze et al. 
noticed  that  activation  of  PPARγ  by  15d-PGJ2,  rosiglitazone  and  trogliglitazone 
inhibited  vascular  smooth  muscle  cell  migration  downstream  of  the  Erk/MAPK 
pathway (69). While ligands did not affect MAPK activity, a later study revealed that 
PPARγ rather inhibits activation of the transcription factor Ets-1 (erythroblastosis virus 
E26 oncogene homolog 1) by MAPK (70). However, in rat peritoneal macrophages, 
15d-PGJ2 significantly attenuated LPS-induced Erk1/2 activation and concomitant IκBα Introduction    19 
degradation (71). Moreover, PPARγ ligands also inhibited vascular endothelial growth 
factor (VEGF)-induced Akt phosphorylation in endothelial cells (72). A  recent study 
might provide explanation how PPARγ interferes with MAPK signaling even though in 
endothelial  cells,  flow  rather  induced  activation  of  Erk5.  However, 
immunoprecipitation experiments revealed a direct interaction between PPARγ-hinge 
helix  1  region  and  Erk5,  resulting  in  an  anti-inflammatory  phenotype  (73).  Still, 
underlying molecular mechanisms of MAPK inhibition remain unclear and it has to be 
clarified if PPARγ ligands act independently of PPARγ or not (Figure 3.4 C).  
 
Even though,  PPARγ/RXR  heterodimers  are postulated  to  facilitate  interaction  with 
transcription factors, co-activators and inhibition of the MAPK cascade, evidence for 
the  action  by  the  PPARγ/RXR  heterodimer  is  missing.  Especially  co-
immunoprecipitations  were  done  with  PPARγ  and  not  RXR.  Thus,  it  might  be  that 
PPARγ alone facilitates repression by the indicated mechanisms.  
(D) SUMOylation-dependent prevention of co-repressor clearance 
Co-activator/co-repressor exchange is a common mechanism controlling the switch 
from gene repression to gene activation and vice versa (74). Recent studies proposed 
that PPARγ prevents signal-mediated clearance of co-repressors and concomitant gene 
induction of a subset of pro-inflammatory mediators (Figure 3.4 D) (75). Pascual et al. 
observed  that  under  basal  conditions  the  co-repressor  complex  containing  NCoR, 
HDAC3,  transducin  beta-like  protein-1  (TBL1)  and  TBL-1  related  protein  (TBLR1),  is 
associated  to  the  κB-RE  within  the  iNOS  promoter.  Upon  LPS  exposure  NCoR  and 
HDAC3 were cleared from the promoter by ubiquitination and subsequent degradation 
by  the  19S  proteasome.  In  response  to  rosiglitazone  PPARγ  was  SUMOylated  and 
targeted  to  NCoR  thereby  preventing  recruitment  of  the  ubiquitination/19S 
proteasome machinery. PPARγ contains two potential SUMOylation sites at K77 and 
K365  (Figure  3.3).  Pascual  et  al.  identified  K365  by  point  mutation  (K365R),  which 
abolished the interaction of PPARγ with the NCoR complex. Conjugation of SUMO1 to 
PPARγ was facilitated by SUMO E2 ligase Ubc9 and the SUMO E3 ligase PIAS1 (protein 
inhibitor  of  activated  STAT1),  originally  identified  to  inhibit  interferon-dependent 
transcription (76). Silencing of Ubc9 and PIAS1 respectively restored LPS-induced NFκB 
transactivation despite treatment with rosiglitazone (77). Prevention of co-repressor Introduction    20 
clearance was recently extended to the nuclear receptors liver X receptor (LXR) α and 
β, assuming gene- and signal-specific regulation of NCoR. Thus, they gave evidence 
that TLR3- and 4-dependent iNOS expression is repressed by LXR and PPARγ, while 
TNFα but not IL1-β synthesis is inhibited by PPARγ. For explanation they found that 
TAB2, another component of the co-repressor complex, is associated to the iNOS and 
TNFα promoter but not to the IL-1β promoter under basal conditions. Knock-down of 
TAB2 reduced LPS-induced iNOS expression, which was further inhibited by LXR but 
not PPARγ (75). Thus, SUMOylation-dependent transrepression by nuclear receptors 
seems to be a general but very specific mechanism of negative regulation of gene 
expression.  
(E) Inhibition of cytosolic PKCα activation by direct interaction  
Besides  repression  of  gene  induction,  ligand-binding  of  PPARγ  also  reduces  the 
oxidative burst, which was in part attributed to an inhibited PKCα signaling required 
for assembly and activation of the NADPH oxidase complex (78, 79). PKCα belongs to 
the classical PKCs and is physiologically activated by diacylglycerol (DAG) and Ca
2+. 
PPARγ dependent inhibition was attributed to an increased expression of the DAG 
kinase α, which lowers the amount of DAG and therewith attenuates PKCα activation 
(80).  Since  oxidative  burst  is  attenuated  within  minutes  and  protein  expression 
requires longer time periods, a new mechanism was recently proposed based on direct 
protein-protein  interaction.  PKCα  activation  is  accompanied  by  membrane 
translocation, which was inhibited upon pre-treatment with rosiglitazone. The use of a 
dominant-negative  mutant  of  PPARγ  supported  the  notion  that  PKCα  inhibition  by 
ligands  was  PPARγ-dependent  and  not  due  to  receptor-independent  effects.  Co-
immunoprecipitation assays and the two-hybrid system pointed to a direct interaction 
of  PPARγ  and  PKCα,  whereas  the  hinge  helix  1  domain  of  PPARγ  seemed  to  be 
responsible for binding (81). Since PPARγ was assumed to be exclusively located in the 
nucleus and PKCα is restricted to the cytosol, von Knethen et al. further gave evidence 
that a portion of PPARγ is actively transported to the cytosol (Figure 3.4 E) (81). 
3.3.4  PPARγ in diseases 
The finding that the antidiabetic drugs TZDs are direct ligands of PPARγ, established 
the receptor as a potent target for the treatment of type-2 diabetes. TZDs were found Introduction    21 
to improve insulin action and to lower blood glucose levels via activating PPARγ. Type-
2 diabetes is associated with increased plasma levels of free fatty acids concomitantly 
causing  insulin  resistance.  The  beneficial  effect  of  PPARγ  is  attributed  to  different 
functions. First, the activation of PPARγ results in an increase of adipocytes, which is 
due  to  enhanced  adipogenesis  and  concomitantly  higher  capability  of  fat  storage. 
Furthermore, PPARγ induces adiponectin, a multimeric plasma protein correlating with 
improved glucose uptake and repressed hepatic glucose output (50).  
Besides  type-2  diabetes,  TZDs  are  under  investigation for  their  potential  beneficial 
effects  on  chronic  inflammatory  diseases  including  inflammatory  bowel  diseases, 
rheumatoid arthritis or multiple sclerosis (MS).  
Inflammatory bowel diseases i.e. ulcerative colitis (UC) and Crohn’s disease are both 
chronic  inflammatory  diseases  where  the  interplay  between  genetic  and 
environmental factors leads to an abnormal immune response of the gut affecting the 
intestinal  mucosa.  Treatment  of  mice  with  rosiglitazone  decreased  symptoms  of 
induced colitis in a murine model. Moreover, heterozygous PPARγ
+/- mice were more 
susceptible to induced colitis and showed higher levels of TNFα and IL-1β (67, 82). In a 
phase II clinical trial, Lewis et al. observed in patients treated with rosiglitazone clinical 
remission concluding that rosiglitazone treatment was efficacious in the treatment of 
mild to moderately active UC (83). Remarkably, patients with UC displayed reduced 
PPARγ  expression  in  epithelial  cells,  whereas  colon  epithelial  cells  of mice  showed 
rather increased expression levels (84).  
MS is an autoimmune disease which is characterized by inflammation of the central 
nervous system resulting in axon demyelination (85). Similar to UC, peripheral blood 
mononuclear  cells  (PBMCs)  from  patients  with  MS  showed  decreased  PPARγ 
expression, whereas microglia and astrocytes from a MS mouse model (experimental 
allergic encephalomyelitis (EAE)) rather showed enhance expression. However, several 
studies  have  shown  beneficial  effects  of  PPARγ  agonists  on  clinical  and 
histopathological features of EAE (86). Treating PBMCs from MS patients with PPARγ 
agonists suppressed proliferation and cytokine expression and prevented PPARγ down-
regulation (87).  Introduction    22 
PPARγ was also implicated in Alzheimer’s disease, rheumatoid arthritis and psoriasis, 
all sharing a hyper-inflammatory response, thus suggesting that treatment with PPARγ 
ligands might be beneficial (88-90). 
3.4  The impact of apoptotic cells on macrophages 
3.4.1  Apoptosis 
A wide spectrum of different types of cell death has been described by now including 
apoptosis, autophagy, cornification and necrosis (91). Still, apoptosis is considered to 
be  the  predominant  way  of  dying  and  is  an  important  feature  to  maintain  tissue 
homeostasis  in  multicellular  organisms.  Apoptosis  is  a  tightly  regulated,  energy-
dependent process, therewith also called programmed cell death. It is characterized by 
morphological changes such as nuclear condensation and fragmentation, cell shrinkage 
and controlled cell disintegration through the formation of membrane vesicles, known 
as ‘apoptotic bodies’, whose membrane integrity is maintained (92, 93). The whole 
process is immunologically silent, primarily because apoptotic cells and debris provide 
signals  for  a  rapid  clearance  by  phagocytes,  ensuring  termination  of the  apoptotic 
program. In contrast to apoptosis, necrosis is characterized by cell swelling, membrane 
disrupture  and  following  release  of  cell  contents,  which  finally  provokes  an 
inflammatory response.  
3.4.2  Engulfment of apoptotic cells - efferocytosis 
Clearance of AC by professional phagocytes such as dendritic cells and macrophages is 
crucial  for tissue homeostasis  and  resolution of  inflammation.  The uptake  of  AC  – 
termed  as  efferocytosis  –  avoids  secondary  necrosis  but  also  actively  shifts 
macrophages towards an anti-inflammatory phenotype. The clearance of AC is a tightly 
regulated process, which can be divided into three steps:  
A)  sensing  of  AC,  B)  specific  recognition  of  AC  and  C)  the  engulfment  of  AC  by 
phagocytes (94). 
A) Sensing of AC by phagocytes 
Similar to inflammation, where immune cells are recruited to the sites of infection, so 
called ‘find-me’ signals attract phagocytes to apoptotic sites, since they may not be in 
close proximity to the dying cells. Several ‘find-me’ signals are described so far. During Introduction    23 
apoptosis, the inactive enzyme tyrosyl-tRNA synthetase is cleaved and two fragments 
are  released.  The  C-terminal  fragment  is  an  endothelial-monocyte-activating 
polypeptide  II  (EMAP  II)  –like  cytokine  and  shows  like  EMAP  II  itself,  chemotactic 
activity (95). Furthermore, apoptotic cells secrete lysophosphatidylcholine (LPC) (96). 
During  apoptosis,  caspase-3  activates  the  calcium-independent  phospholipase  A2, 
which hydrolyses the membrane phospholipid phosphatidylcholine to arachidonic acid 
and LPC. LPC triggers a phagocyte chemotactic response by binding to the G-protein 
coupled  receptor  G2A  (97).  Recruiting  macrophages  to  damaged  sites  initiates  an 
immunosuppressive  phenotype  in  macrophages,  thus  implicating  anti-inflammatory 
properties of LPC. Even though, LPC was originally seen to stimulate pro-inflammatory 
cytokine production and was linked to atherosclerosis (98). Recently, another lipid was 
implicated in sensing AC. Sphingosine-1-phosphate (S1P) is released from apoptotic 
cells (99) and stimulates chemotaxis of primary monocytes and macrophages in vitro 
(100). Besides phagocyte attraction, S1P also exerts anti-inflammatory properties on 
macrophages, which will be described in more detail below.  
B) Recognition of AC by phagocytes 
After  attraction  towards  AC,  phagocytes  need  to  distinguish  between  pathogens, 
apoptotic, necrotic and living cells. Therefore, they recognize AC-associated molecular 
patterns (ACAMPs) or so called ‘eat-me’ signals at the cell surface, which are specific 
for apoptotic cell death. ACAMPs are recognized via specific receptors, often coupled 
to soluble bridging molecules, which strengthen their recognition. The most prominent 
and most discussed ‘eat-me’ signal is phosphatidylserine (PS). As a component of the 
cell membrane, PS is actively stored at the inner leaflet by the aminophospholipid 
translocase  in  living  cells  (101,  102).  During  apoptosis,  PS  is  exposed  at  the  outer 
leaflet of the membrane by the activation of the scramblase and concomitant loss of 
aminophospholipid translocase activity (103, 104). Masking of PS almost completely 
abrogated apoptotic cell uptake, suggesting a key role of PS during efferocytosis (105). 
Various receptors and bridging molecules are known and will be described briefly. The 
bridging molecules Gas6 and milk-fat globule epidermal growth factor 8 (MFG-E8) bind 
PS and in turn are recognized by their receptors Mer tyrosine kinase receptor (MerTK) 
and vitronectin receptor (VnR). Since the first identified PS receptor acting without the 
help of bridging molecules (106) was subsequently demonstrated to be located in the Introduction    24 
nucleus and dispensable for phagocytosis (107), three novel and more promising PS 
receptors at the surface of phagocytes (Tim4, BAI1 and Stabilin2) were discovered 
(108-110). 
Beside  PS,  apoptotic  cells  carry  oxLDL-like  sites,  which  are  recognized  by  different 
scavenger receptors (SR), such as SR A, lectin-like oxLDL receptor 1 or CD36. The latter 
one also links AC to phagocytes via thrombospondin-1 binding (111). Single blocking of 
those  receptors  often  results  in  a  partial  reduction  of  AC  uptake,  suggesting  that 
different receptors and pathways act in concert.  
C) Engulfment of apoptotic cells  
Signaling pathways triggering the engulfment of AC emerge from the interactions of 
‘eat me’ signals with their receptors regulating the GTPases Rho and Rac. Activation of 
Rac  and  Rho  is  accompanied  by  cytoskeletal  re-organization  (112)  and  following 
ingestion in a ‘zipper-like’ process. Genes involved in the engulfment machinery were 
identified  in  the  model  organism  Caenorhabditis  elegans  (113).  The  proteins  have 
mammalian homologues, whose functional properties in phagocytosis of AC are now 
being confirmed (111). A complex containing CrkII (CT10 regulator of kinase II), ELMO1 
(engulfment  and  cell  motility  1)  and  DOCK180  has  been  identified  to  function 
upstream of Rac. Upon AC recognition by VnR (114) or Mer (112), the complex is 
recruited to the plasma membrane triggering nucleotide exchange and activation of 
Rac. ELMO1 is an adapter molecule, whereas DOCK180 contains a guanine exchange 
function,  the  so  called  Docker  domain.  Silencing  DOCK180  by  siRNA  in  J774 
macrophages abolished their phagocytic activity. Moreover, association of DOCK180 
and ELMO1 seems to be required for Rac activation. CrkII also associates to DOCK180 
and ELMO1, whereas its function remains unknown (94).  
Besides the mentioned receptors Mer and VnR, also CD36 (115), annexin1 (116) and 
stabilin-2 seem to regulate AC uptake (108), even though detailed mechanisms remain 
unclear.  Recently,  a  Rac-independent  signal  pathway  was  postulated, showing  that 
ATP-binding  cassette  transporter  A7  and  low-density  lipoprotein  receptor-related 
protein  1  enhance  clearance  of  AC  in  an  Erk-dependent  manner  (117).  However, 
mechanistic studies are obscure.  Introduction    25 
3.4.3  Immunological consequences of phagocytosis of apoptotic cells 
In the late 1990’s Voll et al. observed that LPS-induced TNFα and IL-1β expression in 
monocytes was reduced after co-culture with apoptotic lymphocytes, whereas IL-10 
was up-regulated (118). In the meantime these early studies were supported by many 
others, corroborating the ability of AC to repress macrophage inflammatory responses 
(Figure 3.5). AC provide signals to directly influence the phenotype of their ‘captors’, 
thereby  dampening  inflammation.  Obviously,  suppression  of  inflammation  is  an 
intrinsic  feature  of  apoptotic  cell  death,  even  though  phagocytosis  per  se  is  not 
required.  Studies  in  CD14  deficient  mice  showed  impaired  phagocytosis  of  AC  but 
elevated TGFβ and reduced TNFα secretion (119). This was supported by Lucas et al. 
using CD36 and αvβ3 integrin deficient mice. CD36 and αvβ3 integrin contributed to AC 
clearance,  but  were  not  essential  for  immunosuppression  e.g.  attenuating  TNFα 
production (115).  
Although alternative activation of macrophages by the interaction with AC is widely 
accepted,  the  type  of  macrophage/AC  interaction  as  well  as  underlying  molecular 
signaling circuits are ill-defined. Some of the inhibitory effects were attributed to PS, 
but  generalized  effects  and  details  are  controversial  as  outlined  in  the  following 
paragraphs.  
3.4.3.1  Attenuated ROS and NO formation  
Bactericidal capacity of macrophages is in part mediated by the production of ROS 
(120) and NO. In response to LPS and/or IFNγ, macrophages up-regulate iNOS, which 
catalyzes the oxidation of L-arginine to L-citrulline and NO (121). While it is accepted 
that  AC  reduce  NO  production,  several explanations  are  discussed.  It  is  commonly 
believed that reduced NO formation results from increased arginase expression. Two 
isoforms,  arginase  1  and  2,  metabolize  L-arginine  to  urea  and  ornithine,  thus 
competing with iNOS for the same substrate (122). It is proposed that AC up-regulate 
arginase  1,  at  the  same  time  down-regulating  iNOS  in  a  TGFβ-  and  PS-dependent 
manner (123). Others reported cell-cell-contact- and TGFβ-independent up-regulation 
of arginase 2 triggered by soluble factors secreted by AC (124). Although reduced NO 
formation was linked to the TGFβ/arginase 1 axis (125), it was questioned whether 
TGFβ  alone  induces  arginase  1  expression  in  RAW264.7  macrophages  (126).  In 
addition, expression of arginase 1 occurred late compared to NO inhibition, which Introduction 
argues for additional inhibitory mechanisms. Likely, the rapid induction of arginase 2 
seen  with  AC  contributes  to 
macrophages with secondary and late inhibition being, at least in part, TGFβ
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Another feature of macrophage cytotoxicity is the production of ROS. The oxidative 
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NADPH oxidase complex (78, 79). ROS formation in macrophages was inhibited by 
apoptotic Jurkat cells as well as PS-enriched viable Jurkat cells, whereas oxidized PS 
was even more effective (127). Transwell-experiments pointed to the requirement for 
cell-cell-contacts and possibly a PS-dependent pathway. Mechanistically, Johann et al. 
suggested PPARγ, activated by AC by a so far unknown mechanism, to account for ROS 
inhibition (128). Activation of PPARγ with synthetic agonists induced a direct protein 
interaction with PKCα, thereby interfering with translocation of the kinase from the 
cytosol to the membrane, which is a prerequisite for oxidative burst activation (81).  
3.4.3.2  Modulation of cytokine expression  
Besides  repressing  ROS  and  NO  formation,  AC  strongly  suppress  pro-inflammatory 
cytokine expression of e.g. IL-1β, TNFα, IL-6 and IL-12, subsequent to LPS stimulation. 
Different explanations are plausible and reduction was tied to autocrine signaling of 
TGFβ,  platelet-activating  factor  (PAF)  and  PGE2,  all  of  which  are  released  from 
macrophages in response to AC in a PS-dependent manner. The reduction in IL-1β, IL-8 
and  TNFα,  seen  with  incubation  periods  of  more  than  18  h,  was  abolished  by  a 
neutralizing  TGFβ-antibody,  blocking  cyclooxygenase  (COX)  with  indomethacin  or  a 
PAF receptor antagonist (129).  
A prominent cytokine being up-regulated by AC is TGFβ. Supportive argumentation for 
the PS-dependence came from experiments using human monomyelocyte cells, which 
do not expose PS at their surface during UV-induced apoptosis. These cells failed to 
promote TGFβ1 secretion, while TGFβ release was seen with PS-exposing apoptotic 
Jurkat  cells  (130).  Moreover,  masking  PS  on  irradiated  tumor  cells  by  annexin  V 
averted  TGFβ  production  in  macrophages  (131).  A  recently  reported  PS-receptor, 
Stabilin-2,  mediated  AC  engulfment  and  anti-Stabilin-2  antibodies  induced  TGFβ, 
supporting  the  indirect notion that  PS-receptor  activation triggers TGFβ  expression 
(108). Enhanced TGFβ secretion in response to AC is facilitated by transcriptional and 
translational regulation. TGFβ mRNA transcription was sensitive to p38 MAPK, Erk and 
Jnk inhibition, while translation demands Rho kinase, followed by phosphorylation of 
PI3K/Akt and mTOR (mammalian target of rapamycin) and subsequent activation of 
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3.4.3.3  Inhibition of NFκB  
Even  though  TGFβ  is  a  known  anti-inflammatory  mediator  (133),  reduced  cytokine 
expression  is primarily associated  with  inhibition  of  NFκB.  Identifying  Mer tyrosine 
kinase as a potential candidate to block NFκB, strengthens a role for PS in this process. 
Over-expression  of  a  Mer  kinase-dead  mutant  relieved  NFκB  inhibition  (134).  In 
dendritic cells the Mer kinase receptor was associated with NFκB inhibition in response 
to AC by using Mer receptor knock-down cells and blocking antibodies (135). Future 
studies need to provide mechanistic details, especially as a direct role for inhibition of 
pro-inflammatory cytokine formation via this receptor was still missing.  
Despite  a  potential  role  of  the  Mer  kinase  or  TGFβ  in  down-regulating  pro-
inflammatory  mediators,  the  macrophage  shift  towards  an  anti-inflammatory 
phenotype also occurred independently of PS and TGFβ, especially at earlier times, i.e. 
below 18 h. Cvetanovic et al. provided evidence that NFκB, although being inactive 
binds to the DNA, implying that co-activators/co-repressors are involved (136). But still 
the mechanism remained so far elusive. For tumor-associated macrophages, showing a 
similar phenotype as macrophages, which interacted with AC, it has been proposed 
that  p50  homodimer  formation  accounts  for  NFκB  inhibition  (137).  Although  not 
formally  shown  for  macrophages  polarized  by  AC,  it  opens  the  possibility  that, 
depending on the polarization signal distinct but qualitatively equivalent mechanisms 
interfere with NFκB activation.  
3.4.3.4  S1P and IL-10 in regulatory macrophage polarization  
There  is  evidence  that  soluble  factors  released  from  AC  polarize  macrophages. 
Examples comprise IL-10 (138), TGFβ (139) and more recently the lipid mediator S1P 
(99). During a co-culture of tumor cells with primary macrophages, apoptosis in tumor 
cells  occurred  and  in  turn  macrophages  were  alternatively  activated.  Interrupting 
apoptosis by over-expressing Bcl-2 in tumor cells or using an apoptosis-resistant tumor 
cell line failed to induce the accompanying anti-inflammatory macrophage phenotype 
shift. Interestingly, conditioned medium from AC also polarized macrophages, which 
indisputably argues for a soluble factor transmitting information to macrophages. S1P, 
described  for  its  anti-inflammatory  (140,  141)  and  anti-apoptotic  effects  (142), 
emerged  as  a  potential  candidate.  Indeed,  S1P  is  released  from  AC,  protected Introduction    29 
macrophages against apoptosis, reduced TNFα and IL-12p70 secretion but enhanced 
the expression of IL-10 and IL-8 (143).  
Expression of macrophage IL-10 in response to AC was first noticed in the seminal 
paper  by  Voll  et  al.  (118).  IL-10  emerged  as  a  key  regulator  in  suppressing  Th1 
responses. Strikingly, IL-10 deficient mice developed chronic intestinal inflammation, 
as they apparently could not restrict inflammation (144). Especially in macrophages, 
which  express  high  levels  of  IL-10R,  the  immunosuppressive  role  of  IL-10  was 
intensively  characterized.  IL-10  activates  STAT3  homodimer  formation  and  DNA 
binding,  with  the  consequence  of  suppressing  pro-inflammatory  mediator 
transcription (26). Regarding the question how IL-10 is induced by AC, it is tempting to 
attribute  this  to  COX-2  expression  (145).  COX-2  is  rate  limiting  in  converting 
arachidonate to PGE2, with the further conversion of PGE2 towards anti-inflammatory 
mediators such as the PPARγ agonist 15d-PGJ2 or resolvins (33). COX-2 expression in 
macrophages  by  AC  is  either  facilitated  via  the  VnR  (146),  which  requires  cell-cell 
contacts between AC and macrophages, or by AC-derived S1P and HuR-mediated COX-
2 mRNA stabilization (147). Strikingly, efferocytosis-dependent PGE2 production was 
shown to markedly impair pathogen clearance by lung alveolar macrophages in vivo, 
consistent with elevated levels of IL-10 (148).  
A  knock-down  of  sphingosine  kinase  2  in  tumor  cells  reduced  S1P  levels  in  the 
supernatant  of  AC,  at  the  same  time  interrupting  to  a  great  extent  the 
immunosuppressive properties of AC supernatants. S1P not only induced COX-2, but 
also up-regulated heme oxygenase-1 (HO-1) in a biphasic manner. Early expression of 
HO-1 after 6 h was transmitted by activating the S1P receptor 1, whereas a second 
wave  of  expression  was  attributed  to  autocrine  signaling  of  VEGF  A  (149).  HO-1 
catalyzes the rate limiting step in the degradation of heme to biliverdin, ferrous iron 
and  carbon  monoxide  and  is  known  for  its  anti-apoptotic  and  anti-inflammatory 
properties  (150-152).  HO-1  was  causatively  involved  in  up-regulation  of  Bcl-2  and 
Bcl-XL,  explaining  the  mechanism  behind  S1P-mediated  protection  from  apoptosis 
(149).  
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3.5  Aims of the study 
PPARγ  plays  an  eminent  role  during  alternative  activation  of  macrophages  and 
resolution of inflammation. As an anti-inflammatory signaling molecule, it seems likely 
that it is tightly regulated dependent on the state of the immune response. There is 
growing  evidence  that  PPARγ  expression  is  reduced  during  inflammation,  whereas 
molecular mechanisms are ill-defined. Even though, its role in immunosuppression is 
getting more definite. AC provoke an active repression of pro-inflammatory responses 
inter  alia  by  the  inhibition  of  pro-inflammatory  cytokine  expression  or  attenuated 
generation of reactive oxygen species. The reduced oxidative burst was attributed to 
PPARγ activation, while mechanisms behind the reduced cytokine expression remained 
unclear. 
The  first  part  of  my  thesis  dealt  with  the  question  whether  AC-provoked  NFκB 
inhibition  in  macrophages  depends  on  PPARγ.  Furthermore,  I  was  intrigued  to 
investigate underlying mechanisms repressing NFκB transactivation. Thus, this study 
should allow to further understand how AC effect macrophage plasticity associated 
with decreased pro-inflammatory cytokine production.  
The  second  part  of  my  Ph.D.  thesis  addressed  regulation  mechanisms  of  PPARγ 
expression during the inflammatory response, which was initiated by LPS treatment. 
Special interest was set on the question, if altered mRNA was due to transcriptional or 
post-transcriptional  changes,  subsequently  investigating  detailed  mechanisms. 
Clarification  of  pathway  decreasing  PPARγ  expression  might  help  to  understand 
disease  conditions  thus  providing  options  for  new  therapeutic  approaches  during 
chronic inflammation.  
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4  Material and Methods 
4.1  Material 
4.1.1  Cells 
Jurkat T cells 
Jurkat T cells are derived from a 14-year-old boy with acute lymphatic leukemia. This T 
cell line was established in 1977 (153). 
Murine splenocytes 
Primary  murine  splenocytes  were  isolated  from  C57BL/6  PPARγ
fl/fl  or 
LysMCre
+/+/PPARγ
fl/fl  mice.  All  procedures  performed  on  these  mice  followed  the 
guidelines of the Hessian animal care and use committee. 
Primary human monocytes 
Primary human monocytes were isolated from buffy coats, which were obtained from 
DRK-Blutspendedienst Baden-Württemberg-Hessen, Frankfurt. 
RAW 264.7 cells 
RAW 264.7 mouse monocytes/macrophages were established from ascites of a tumor 
induced in a male mouse by intraperitoneal injection of Abselon Leukaemia Virus (A-
MuLV) in 1977 (154). 
THP-1 cells 
THP-1 human monocytes were obtained from the peripheral blood of a 1-year-old boy 
with acute monocytic leukemia at relapse in 1978 (155). 
4.1.2  Bacteria 
Competent  bacteria  strains  were  provided  by  Stratagene  GmbH  (Amsterdam,  The 
Netherlands). XL1-Blue® supercompetent cells were generally used for amplification. 
Vectors mutated with QuikChange XL II site directed mutagenesis kit were transformed 
in  XL10-Gold®  ultracompetent  cells.  For  generation  of  unmethylated  DNA,  vectors 
were transformed in the Dam
- bacteria strain SCS110®. Genotypes are described in 
Table 4.1, while the listed genes signify mutant alleles.  
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Table 4.1: Bacteria strains 
 
Bacteria strain  Genotype 
XL1-Blue 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB lacIqZ.M15 
Tn10(Tetr)]. 
XL10-Gold 
TetrD(mcrA)183  D(mcrCB-hsdSMR-mrr)173  endA1  supE44  thi-1  recA1 
gyrA96 relA1 lac Hte [F´ proAB lacIqZDM15 Tn10 (Tetr) Amy Camr]. 
SCS110 
rpsL (Str
r) thr leu endA thi-1 lacY galK galT ara tonA tsx dam dcm supE44 
Δ(lac-proAB) [F´ traD36 proAB lacIqZΔM15] 
 
4.1.3  Chemicals and reagents 
All  chemicals  were  of  highest  grade  of  purity,  commercially  available  and  usually 
purchased from Sigma-Aldrich GmbH (Deisenhofen), Roth GmbH (Karlsruhe) or Merck 
Eurolab  GmbH  (Darmstadt).  Cell  culture  media  and  supplements  came  from  PAA 
(Cölbe). Special reagents and kits are listed in the table below.  
Table 4.2: Special reagents and kits 
 
Chemical/Kit  Provider 
12-Tetradecanoyl-phorbol-13-acetate (TPA)  Sigma-Aldrich GmbH (Deisenhofen) 
Absolute™ qPCR SYBR® Green Fluorescein Mix  ABgene (Hamburg) 
Allstars negative control siRNA  Qiagen GmbH (Hilden) 
Amaxa® Nucleofector® Kits (V and Human Macrophages)  Lonza Cologne AG (Köln) 
Bay 11-7082  Sigma-Aldrich GmbH (Deisenhofen) 
CD11b Microbeads (mouse)  Miltenyi Biotec GmbH (Bergisch-Gladbach) 
Chelex® 100  BioRad GmbH (Munich) 
Cycloheximide  Sigma-Aldrich GmbH (Deisenhofen) 
Deoxynucleotide Solution Mix (dNTPs)  New England Biolabs (Frankfurt) 
D-luciferine  AppliChem GmbH (Darmstadt) 
DRB (5–6 dichloro-1-β- ribofuranosyl-benzimidazole)  Sigma-Aldrich GmbH (Deisenhofen) 
GW9662  Alexis Biochemicals (Lausen, Switzerland) 
HiSpeed Plasmid Maxi Kit  Qiagen GmbH (Hilden) 
In-Fusion™ Dry-Down PCR Cloning Kit 
Clontech-Takara (Saint-Germain-en-Laye, 
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Interferon g g g g (human)   Roche Diagnostics GmbH (Mannheim) 
iScript™ cDNA Synthesis Kit  BioRad GmbH (Munich) 
JetPEI™ transfection reagent  Polyplus transfection (Illkirch, France) 
Leptomycin B  Sigma-Aldrich GmbH (Deisenhofen) 
Lipopolysaccharide (from Escherichia coli, serotype 
0127:B8)  
Sigma-Aldrich GmbH (Deisenhofen) 
Luminol (3-Aminophtalhydrazide)  Acros Organics (Geel, Belgium) 
Lymphocyte separation medium (Ficoll)  PAA Laboratories GmbH (Cölbe) 
Anti-miR™ - miRNA Inhibitors (neg. control, miR-27a, 
miR-27b) 
Applied Biosystems/Ambion, Austin, TX, 
USA 
miR-27a and b mimic  Qiagen GmbH (Hilden) 
miScript Reverse Transcription Kit  Qiagen GmbH (Hilden) 
miScript SYBR® Green PCR Kit  Qiagen GmbH (Hilden) 
Normal rabbit IgG  Millipore/Upstate (Billerica, MA, USA) 
ON-TARGETplus SMARTpool siRNA (murine NCoR1 and 
PIAS1) 
ThermoScientific GmbH (Lafayette, CO, 
USA) 
peqGOLD RNAPure™  PeqLab Biotechnologie GmbH (Erlangen) 
Proteinase K  New England Biolabs (Frankfurt) 
Protein G-Agarose  Roche Diagnostics GmbH (Mannheim) 
QuikChange® XL II site directed mutagenesis kit  Stratagene (Amsterdam, The Netherlands) 
Restriction enzymes (XbaI, Bpu10I and NcoI)  New England Biolabs (Frankfurt) 
Rosiglitazone  Alexis Biochemicals (Lörrach) 
SB203580 (p38 inhibitor)  Sigma-Aldrich GmbH (Deisenhofen) 
Standard DC Protein Assay Kit  BioRad GmbH (Munich) 
Taq DNA Polymerase, recombinant  Invitrogen GmbH (Karlsruhe) 
TNFα (human, recombinant)  Roche Diagnostics GmbH (Mannheim) 
Trichostatin A  Sigma-Aldrich GmbH (Deisenhofen) 
 
4.1.4  Antibodies 
Secondary  antibodies  (IRDye800-labelled  anti-mouse,  IRDye800-labelled  anti-rabbit) 
were obtained from Li-COR Biosciences GmbH (Bad Homburg). Primary antibodies are 
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Table 4.3: Primary antibodies 
 
Antibody  Provider 
Dilution used for WB 
analysis 
Anti-actin  Sigma-Aldrich GmbH (Deisenhofen)  1:2000 
Anti-tubulin  Sigma-Aldrich GmbH (Deisenhofen)  1:1000 
Anti-NCoR  Affinity Bioreagents (Golden, CO, USA)   
Anti-PPARγ (H-100X)  Santa Cruz Biotechnology, Inc. (Heidelberg)  1:2000 
 
4.1.5  Plasmids 
Used plasmids are listed in the tables below (Table 4.4 and Table 4.5). 
Table 4.4: Reporter plasmids 
 
Plasmid  Information  Provider 
pGL3-control 
Contains a SV40 promoter upstream of the luciferase 
encoding region, ampicillin resistance 
Promega 
(Mannheim)  
pGL3-basic 
Contains  a  minimal  promoter  upstream  of  the 
luciferase encoding region, ampicillin resistance 
Promega 
(Mannheim)  
pNFκB-Luc 
Contains  three  κB  sites  and  a  minimal  promoter 
upstream of the luciferase encoding region 
(156) 
pAOX-TK 
Contains the promoter of the acyl CoA oxidase (AOX) 
upstream of the luciferase encoding region 
(157) 
pGL3γ1p3000, 
pGL3γ3p800 
Contains the different PPARγ promoters upstream of 
the luciferase encoding region 
(39, 41) 
 
Table 4.5 Expression plasmids 
 
Plasmid  Description  Provider 
pcDNA3-PPARg g g g1 and  
pcDNA3-PPARg g g g1-AF2 mt 
codes for human PPARγ1 protein, the mutant carries 
the mutations L466A/E469A, ampicillin resistance 
V.K.K. Chatterjee, 
University of 
Cambridge, UK  
pDsRed-PPARγ1 and  
deletion constructs 
codes  for  DsRed-PPARγ1  fusion  protein,  parts  of 
PPARγ1 are deleted for structure analysis 
(81) 
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4.1.6  Oligonucleotides 
Oligonucleotides  were  purchased  from  Biomers.net  GmbH  (Ulm)  and  described  in 
Table 4.6. Changed nucleotides of primers used for point mutation with QuikChange 
are underlined. PPARg1, actin and PIAS1 were determined using QuantiTect Primer 
Assay from Qiagen GmbH (Hilden).  
Table 4.6: Oligonucleotides 
 
Primer  Forward  reverse 
annealing 
temperature 
18S rRNA (human)  5’-GTAACCCGTTGAACCCCATT-3’  5’-CCATCCAATCGGTAGTAGCG-3’  55°C 
Actin (human) 
5´-TGACGGGGTCAC 
CCACACTGTGCCCATCTA-3´ 
5´-CTAGAAGCATTT 
GCGGTGGACGATGGAGGG-3´ 
55°C 
ChIP-TNFα (mouse)  5´-GGCTTGTGAGGTCCGTGAAT-3´  5´-GAAAGCTGGGTGCATAAGGG-3´  56°C 
DsRed  5´-GAGGTGCAGCAGGACTCCTC-3´  5´-TGGCCTTGTACACGTCTTG-3´  55°C 
GAPDH (mouse)  5´-CTCATGACCACAGTCCATGC-3´  5´-TTCAGCTCTGGGATGACCTT-3´  55°C 
IL-6 (mouse)  5´-GAACAACGATGATGCACTTGC-3´ 
5´-TCTCTGAA 
GGACTCTGGCTTTG-3´ 
55°C 
K77R (QuikChange) 
5´-GAGTACCAAA 
GTGCAATCAGAGTGGAGCCTGC-3´ 
5´-GCAGGCTCCA 
CTCTGATTGCACTTTGGTACTC-3´ 
68°C 
PPARγ-UTR (In-
Fusion) 
5´-GCCGTGTAATTC 
TAGCAGAGAGTCCTGAGCC-3´ 
5´-CCGCCCCGACTC 
TAGTTCATAATATGGTAATTTTTA-3´ 
40°C 
PPARγ-UTR-ΔmiR-
27 (QuikChange) 
5´-GGGAAAATCTGACACCTAAAA 
AGCATTTTAAAAAGAAAAGG-3´ 
5´-CCTTTTCTTTTTAAAATCGTTT 
TTAGGT GTCAGATTTTCCC-3´ 
68°C 
PPARγ transcript 
variant 1  
5’-GGCCCAGCGCACTCGGA-3’    60°C 
PPARγ transcript 
variant 3 
5’-GCTGGTGA 
CCAGAAGCCTGCAT-3’ 
  60°C 
PPARγ exon 1   
5’-GGCCAGAA 
TGGCATCTCTGTGT-3’. 
60°C 
PPRE (EMSA) - 
IRD700-labeled 
5’-CAAAACTA 
GGTCAAAGGTCATCAA-3’ 
5’-TTGATGAC 
CTTTGACCTAGTTTTG-3’ 
 
PPRE mt (EMSA) - 
IRD700-labeled 
5’-CAAAACTA 
GCACAAAGCACATCAA-3’ 
5’-TTGATGTG 
CTTTGTGCTAGTTTTG-3’ 
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NCoR (mouse) 
5´-GCAAAAGT 
AGAGCAGCAGATCC-3´ 
5´-GGGCCAAG 
ACCTTCAAATATTT-3´ 
55°C 
S82A (QuikChange) 
5´-GTGGAGCCTGCA 
TCGCCACCTTATTATTCTGAG-3´ 
5´-CTCAGAATAATA 
AGGTGGCGATGCAGGCTCCAC-3´ 
68°C 
TNFα (mouse) 
5´-CCATTCCT 
GAGTTCTGCAAAGG-3´ 
5´-AAGTAGGA 
AGGCCTGAGATCTTATC-3´ 
55°C 
 
4.1.7  Instruments and Software 
Used instruments and software are listed in Table 4.7 and  
Table 4.8.  
Table 4.7: Instruments 
 
Instruments  Provider 
AIDA Image Analyzer  Raytest GmbH (Straubenhardt) 
Autoclave HV 85   BPW GmbH (Süssen) 
AutoMACS™ Seperator  Miltenyi Biotec GmbH (Bergisch-Gladbach) 
B250 Sonifier   Branson Ultrasonics (Danbury, USA) 
Bacteria clean bench Hera guard  Heraeus GmbH (Hanau) 
Bacteria incubator B5042   Heraeus GmbH (Hanau) 
Bacteria incubator Innova®44  New Brunswick Scientific GmbH (Nürtingen) 
CASY®   Schärfe System (Reutlingen) 
Centrifuge 5415 R and 5810 R  Eppendorf GmbH (Hamburg) 
Hera cell 150 (Lamina)   Thermo Fisher Scientific Inc. (Waltham, MA, USA) 
LabLine Orbit Shaker   Uniequip GmbH (Martinsried) 
Magnetic stirrer Combimag RCH  IKA Labortechnik GmbH & Co. KG (Staufen) 
Mastercycler®   Eppendorf GmbH (Hamburg) 
Mini-PROTEAN 3 System   Bio-Rad Laboratories GmbH (Munich) 
Mithras LB940 multimode reader  Berthold Technologies (Bad Wildbad) 
MyiQ iCycler system  Bio-Rad Laboratories GmbH (Munich) 
NanoDrop ND-1000   Peqlab Biotechnologie GmbH (Erlangen) 
Nucleofector  Amaxa AG (Cologne) 
Odyssey infrared imaging system  Li-COR Biosciences GmbH (Bad Homburg) Material and Methods    37 
Pure water system Purelab Plus   ELGA LabWater GmbH (Siershahn) 
Sub-Cell® GT electrophoresis system   Bio-Rad Laboratories GmbH (Munich) 
Thermomixer 5436   Eppendorf GmbH (Hamburg) 
Trans-Blot SD blotting machine   Bio-Rad Laboratories GmbH (Munich) 
Ultrasonic bath Sonorex  Bandelin electronic GmbH (Berlin) 
UV-Transilluminator gel 
documentation system  
Raytest GmbH (Straubenhardt) 
 
Table 4.8: Software 
 
Software  Provider 
AIDA Image Analyzer  Raytest GmbH (Straubenhardt) 
Clone Manager  SciEd Software (Cary, NC, USA) 
MikroWin 2000  Berthold Technologies (Bad Wildbad) 
MiQ   Bio-Rad Laboratories GmbH (Munich) 
4.2  Methods 
4.2.1  Cell biology 
4.2.1.1  Cell culture 
Jurkat  T  cells,  RAW264.7  mouse  macrophages,  RAW264.7 dominant/negative  (d/n) 
PPARγ  macrophages  and  THP-1  human  monocytes  were  cultured  in  Roswell  Park 
Memorial Institute (RPMI) 1640 medium. Media were supplemented with 10% heat-
inactivated fetal calf serum (FCS), 5 mM glutamine, 100 U/ml penicillin, and 100 µg/ml 
streptomycin. Cells were kept in a humidified atmosphere of 5% CO2 in air at 37°C and 
were transferred twice a week. Cell numbers were determined using the cell counter 
system Casy
®. 
4.2.1.2  Isolation and culture of human monocytes 
Human  monocytes  were  isolated  from  buffy  coats  (obtained  from  DRK-
Blutspendedienst  Baden-Württemberg-Hessen,  Institut  für  Transfusionsmedizin  und 
Immunhämatologie Frankfurt am Main, Frankfurt) using Ficoll-Hypaque gradients as 
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lymphocyte separation media, blood cells were added, followed by density gradient 
centrifugation  (440  x  g,  35  min,  RT).  PBMCs  were  collected,  washed  twice  with 
leukocyte washing buffer and were allowed to adhere to culture dishes (Primaria 3072, 
BD  Becton  Dickinson  GmbH,  Heidelberg)  for  1  h  at  37°C.  Non-adherent  cells  were 
removed.  Monocytes  were  then  differentiated  into  macrophages  with  RPMI  1640 
containing 10% AB-positive human serum, 5 mM glutamine, 100 U/ml penicillin, and 
100 µg/ml streptomycin for 7 days.  
4.2.1.3  Isolation  of  murine  CD11b+  splenocytes  and  differentiation  into 
macrophages 
All isolation steps were performed at 4°C or on ice, respectively. The spleen was placed 
into PBS in a 6 well-plate and homogenized between the frosted ends of two glass 
slides, which were sterilized with ethanol before. The homogenized spleen (in PBS) was 
passed  through  a  70 µm  Filcon  syringe  to  generate  a  single-cell  suspension  and 
transferred into a 15 ml-Falcon tube. The filtered suspension was incubated with 5 ml 
erythrocyte lysis buffer (see Appendix) for 5 min and centrifuged at 500 x g for 5 min. 
Splenocytes were washed with PBS and cell number was determined using Casy®. Up 
to  1*10
8  splenocytes  were  used  for  magnetic  cell  sorting  (see  4.2.1.4).  For 
differentiation of the CD11b
+ splenocytes into macrophages, cells were cultured in the 
presence of 25 ng/ml macrophage-colony stimulating factor (M-CSF) for 5 d (159) in 
RPMI 1640 supplemented with 10% FCS, non-essential amino acids, pyruvate, 5 mM 
glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin.  
4.2.1.4  Magnetic cell sorting 
CD11b
+  splenocytes  were  sorted  using  the  autoMACS  separator.  According  to  the 
manufacturer’s protocol, 1*10
8 cells were washed with PBS and suspended in 800 µl 
(80 µl/1*10
7  cells)  leukocyte  running  buffer  (see  Appendix).  For  magnetic  labelling 
200 µl  (20 µl/1*10
7  cells)  CD11b  microbeads  were  added  and  incubated  on  ice for 
20 min. Cells were washed with 1 ml leukocyte running buffer, centrifuge at 300 x g for 
10 min  and  re-suspended  in  500 µl  running  buffer.  Cells  were  sorted  using  the 
autoMACS  program  “positive  selection”  (<possel>).  The  eluted  fraction  was 
centrifuged at 300 x g for 10 min and supernatant was discarded. Then, cells were re-
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4.2.1.5  Differentiation of THP-1 monocytes 
For differentiation of THP-1 monocytes into macrophages, cells were seeded in the 
appropriate cell number and treated with 50 nM TPA over night. The next day the 
medium was changed and cells were cultured for another 24 h in fresh medium prior 
to experiments.  
4.2.1.6  Generation of apoptotic Jurkat cells 
To  generate  apoptotic  Jurkat  cells,  they  were  cultured  in  FCS-free  medium  and 
stimulated with 0.5 µg/ml staurosporine for 3 h provoking roughly 80% apoptotic cell 
death as described previously (99). Afterwards cells were washed twice with medium 
to  remove  staurosporine.  For  co-culture,  AC  were  re-suspended  in  FCS-containing 
RPMI  1640  medium  and  added  to  macrophages  at  a  ratio  of  5:1.  Following 
experiments  but  prior  to  sample  preparation  non-ingested  AC  were  removed  and 
macrophages washed twice with PBS excluding variations on results by AC as described 
previously (128).  
4.2.1.7  Transient transfection 
Transient transfection with several over-expression vectors and reporter plasmids was 
performed using the JetPEI
Ô transfection reagent. For reporter analysis 1*10
5 THP-1 
cells were seeded in 24-well plates and differentiated with 50 nM TPA over night. 
Medium was changed the next day and cells were transfected after another 24 h. For 
transfection of RAW264.7 macrophages, 5*10
4 cells per well were seeded in 24-well 
plates and also transfected 24 h later. Both cell lines were transfected with 1 µg DNA 
as described by the manufacturer. In brief, 1 µg DNA and 2 µl JetPEIÔ transfection 
reagent were mixed each with 25 µl 150 mM NaCl per well and vortexed briefly. The 
JetPEI mixture was added to the DNA mixture, vortexed, spinned down and incubated 
for 30 min at room temperature (RT). Afterwards 50 µl/well of the mixture were added 
to the cells, incubated for 4 h and then cultured in fresh medium for another 24 h prior 
to experiments.  
Transient transfection of siRNA was performed using the Nucleofector® technology 
from Amaxa biosystems. According to the manufacturer’s protocol, 2*10
6 RAW264.7 
macrophages  or  1.5*10
6  primary  human  macrophages,  which  were  detached  from 
plates by incubating them with 1 x trypsin-EDTA for 2 h, were centrifuged for 10 min at Material and Methods    40 
90 x g and re-suspended in 100 µl Nucleofector® Solution (Nucleofector® solution V for 
RAW264.7  and  Human  Macrophage  Nucleofector®  Solution  for  primary  human 
macrophages). After addition of 3 µg siRNA, 300 pmol miR-inhibitors or 20 pmol of the 
miR-27  mimic  respectively,  cells  were  electroporized  using  program  “D-032”  for 
RAW264.7  or  “Y-010”  for  primary  human  macrophages.  Transfected  cells  were 
immediately  transferred  in  pre-warmed  medium,  seeded  in  3  or  6 cm  plates  an 
cultured for another 48 h.  
4.2.2  Biochemistry 
4.2.2.1  Protein determination (Lowry) 
The protein content of cell lysates was determined using the DC Protein Assay Kit, 
based on the Lowry method (160). Briefly, a standard dilution series of bovine serum 
albumin (BSA) in protein lysis buffer (see Appendix) was prepared (0.625 to 10 mg/ml). 
2 µl of the samples as well as of the standard dilution were pipetted in duplicates into 
a 96-well plate, 20 µl solution A were added, and then the colorimetric reaction was 
started by adding 160 μl of solution B. After incubation for 15 min (RT with shaking), 
extinction was measured at 750 nm using the Mithras LB 940 multimode reader. 
4.2.2.2  Nuclear protein extraction 
3 x 10
6 RAW264.7 macrophages were seeded in 10 cm plates and stimulated with AC 
for 3 h the next day. Cells were washed with ice-cold PBS and lysed with 200 µl ice cold 
hypotonic cell lysis buffer (see Appendix) for 10 min on ice. Nuclei were sedimented by 
centrifugation at 12,000 x g for 1 min and cytosolic fraction was transferred in a new 
tube. Subsequently, sedimented nuclei were lysed with 50 µl nuclear lysis buffer (see 
Appendix),  incubated  for  30 min  on  ice  and  centrifuged  at  12,000  x  g  for  10 min. 
Supernatant was transferred in a new tube and protein content was determined using 
Lowry method (see 4.2.2.1).  
4.2.2.3  SDS-PAGE/Western blot (WB) analysis 
For Western analysis, 2-4*10
6 cells were treated as indicated, scraped off, lysed with 
200 µl  protein  lysis  buffer  and  sonicated  for  8  x  1 s.  Subsequently,  lysates  were 
incubated  on  ice  for  30 min  and  vortexed  every  5 min.  After  centrifugation  (4°C, 
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were determined as described above (see 4.2.2.1). 80 µg of protein were mixed with 
4 x SDS  (sodium  dodecyl  sulfate)  sample  buffer  and  denatured  at  95°C  for  5 min. 
Proteins were separated on 10% SDS-polyacrylamide gels using 1 x SDS-running buffer 
and  the  Mini-PROTEAN  3  system  Proteins  were  transferred  onto  a  nitrocellulose 
membrane  by  semi-dry  blotting.  To  prohibit  unspecific  binding,  membranes  were 
blocked with 5% milk/TTBS for 1 h at RT. Afterwards membranes were incubated with 
antibodies in 5% milk/TTBS at 4°C over night at indicated concentrations (see Table 
4.3). For protein detection, membrane was washed 3 times with TTBS for 7 min and 
incubated with IRDye secondary antibodies (anti-rabbit or anti-mouse; 1:10,000) in 5% 
milk/TTBS  for  1 h  at  RT.  The  membrane  was  washed  again  3  times  for  7 min  and 
proteins  were  detected  and  densitometrically  analysed  using  the  Odyssey  infrared 
imaging system. Buffers are described in the appendix.  
4.2.3  Molecular biology 
4.2.3.1  Reporter assay 
All reporter assays were performed in duplicate. For reporter analysis cells were re-
suspended in 60 µl reporter lysis buffer (see Appendix) and incubated for 15 min under 
shaking at RT. Lysates were cleared by centrifugation at 4,000 x g for 5 min. Reporter 
activity was measured using a Mithras LB 940 multimode reader. Therefore, 20 µl of 
the lysate were transferred in a 96-well plate, 50 µl reporter assay reagent were added 
automatically, plates were shaked for 2 s, and each well measured for 10 s.  
Luciferase activity was normalized to protein concentration of each sample. To control 
transfection  efficiency  concerning  over-expression  of  the  different  pDsRed-PPARg1 
constructs, mRNA levels of DsRed were determined by quantitative PCR.  
4.2.3.2  Chromatin immunoprecipitation (ChIP) assay 
3*10
6 RAW264.7 cells were seeded in 10 cm plates and cultured over night. Before 
cross-linking, cells were pre-treated with AC (90 min) followed by 1 µg/ml LPS (60 min) 
afterwards. ChIP assays were performed as described by Nelson et al. (161). In brief, 
cells were cross-linked by adding 45 µl 37 % formaldehyde/ml medium, shaked at 
200 rpm for 5 min at RT. Afterwards, 80 µl 1 M glycine/ml medium was added and 
incubated for another 5 min with shaking. Cells were scraped off, washed with PBS and 
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12,000 x g. Sedimented nuclei were re-suspended in 400 µl IP buffer and incubated for 
15 min on ice. To shredder genomic DNA, glass beads were added to the lysates and 
sonicated thrice with 15 x 8 pulses. Probes from 2-3 plates were combined before 
precipitation.  To  determine  DNA  fragmentation  and  for  input  control,  DNA  was 
extracted and analysed by agarose gel electrophoresis.  
NCoR was precipitated using 1 µg of anti-NCoR from Affinity Bioreagents (Golden, CO, 
USA), an established ChIP assay antibody (77). For mock-IP, lysates were incubated 
with 1 µg of normal rabbit IgG from Millipore/Upstate (Billerica, MA, USA). 120 µl of 
each lysate were incubated with antibody or IgG for 15 min at 4°C in an ultrasonic bath 
and  cleared  afterwards  by  centrifugation  (12,000 x g,  10  min,  4°C).  Subsequently, 
100 µl of each probe were transferred to a new tube, 30 µl protein G agarose was 
added  and  incubated  for  1-2 h.  To  wash  away  non-bound  proteins,  agarose  beads 
were washed 5 times with 1 ml IP buffer and following centrifugation for 1 min at 
2,000 x g. Afterwards, 100 µl 10% Chelex 100 were added, briefly vortexed and boiled 
at 99°C for 10 min. To digest proteins, 1 µl of proteinase K (20 µg/µl) was added and 
incubated at 37°C for 1 h followed by another 10 min at 99°C for another 10 min. 
Tubes were then centrifuged for 1 min at 12,000 x g. To finally isolate the DNA, 100 µl 
distilled H2O were added, solution was vortexed for 10 s and centrifuged at 12,000 x g 
for 1 min. Approximately 80 µl of the DNA-containing supernatant were transferred in 
a new tube and isolation step was repeated, resulting in a final volume of 160 µl DNA. 
A  211 bp  fragment  of  the  TNFa  promoter,  spanning  an  established  κB-RE,  was 
amplified using up to 5 µl of DNA and the ChIP-TNFα primer (see Table 4.6). For input 
controls, 15% DNA of each probe was used. Resulting fragments were separated at a 
1.5%  agarose  gel  in  0.5  x  TBE.  Finally,  gels  were  stained  in  an  ethidium  bromide 
solution (0.5 mg/l) for 20 min, destained in H2O and visualized by UV excitation.  
4.2.3.3  RNA isolation 
Total  RNA  was  isolated  using  a  PeqGold  RNAPure™  Kit  as  described  by  the 
manufacturer. For mRNA isolation of adherent cells, 1 ml of PeqGold RNAPure™ per 
1-5*10
6 cells was added to the plate, lysed for 5 min and transferred to a 1.5 ml tube. 
After addition of 200 µl chloroform, samples were vortexed thoroughly and incubated 
at  RT for  another  5 min.  Subsequently,  samples  were  centrifuged  at 12,000 x g for 
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interphase. To precipitate RNA, 0.5 ml isopropanol were added to the collected water-
phase,  incubated  for  15 min  at  RT  and  centrifuged  (12,000 x g,  15 min,  4°C). 
Sedimented RNA was washed twice with 75% ethanol in DEPC-treated H2O, dried and 
finally solved in 10-50 µl DEPC-treated distilled H2O by incubation at 56°C for 20 min. 
RNA concentration was determined using optical density (OD) at 260 nm. An OD260 of 1 
is equivalent to a RNA concentration of 40 µg/ml.  
4.2.3.4  Reverse transcription (RT) 
Reverse transcription for determination of RNA content was performed according to 
the provided manual using iScript™ cDNA Synthesis Kit. In brief, 1 µg of isolated mRNA 
were mixed with 4 µl 5 x reaction buffer, 1 µl iScript reverse transcriptase and filled up 
with nuclease-free H2O to 20 µl. The reaction mix was incubated for 5 min at 25°C, 
30 min at 42°C and finally 5 min at 85°C for inactivation of the enzyme. The resulting 
cDNA was diluted 1:5.  
To  analyze  miRNA  expression,  RNA  was  transcribed  using  the  miScript  Reverse 
Transcription Kit. Therefore, 1 µg of RNA were mixed with 4 µl 5x reaction buffer, 1 µl 
of miScript Reverse Transcriptase Mix and filled up with RNAse-free water to 20 µl. The 
mixture was incubated at 37°C for 60 min followed by an inactivation step for 5 min at 
95°C. The resulting cDNA was diluted 1:2.  
4.2.3.5  Polymerase chain reaction (PCR) 
For amplification of DNA, conventional PCR was performed using recombinant Taq 
DNA polymerase according to the manufacturer’s protocol. Briefly, 3 µl forward and 
reverse  primer  (5 µM)  each,  1 µl  dNTP  mix  (10 µM  each),  1.5 µl  MgCl2,  5 µl 
10 x reaction buffer were mixed with template DNA, filled up with distilled H2O to 
49.5 µl and finally 0.5 µl Taq polymerase were added. PCRs were performed according 
to  the  following  profile,  while  annealing  temperature  was  dependent  on  the  used 
primer pairs.  
Initial denaturation    95°C    1 min 
 
Denaturation      95°C    50 s 
Annealing       50-65°C  30 s 
Extension      72°C     90 s 
 
Final extension    72°C    7 min 
30-35 
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4.2.3.6  Quantitative PCR (qPCR) 
For quantitative PCR (qPCR), 2-4 µl of cDNA (see 4.2.3.4) were used and mixed with 
either 2 µl QuantiTect Primer Assay or 0.5 µl forward and reverse primer (5 µM) each, 
10 µl Absolute™ qPCR SYBR ® Green Fluorescein Mix and filled up with distilled H2O to 
20 µl. Determination of miRNA expression was performed using miScript SYBR Green 
and additionally 2 µl of 10 x Universal Primer. The mixtures were transferred to a 96-
well plate, briefly spinned down and the plate sealed with an optical adhesive seal 
sheet. QPCR was performed using the MyiQ Single-Colour Real-time PCR Detection 
System and the following thermal cycling program.  
 
Enzyme activation     95°C    15 min 
 
Denaturation      95°C    15 s 
Annealing       55-60°C  30 s 
Extension      72°C     30 s 
 
To confirm the specificity of the reaction, a melt curve was created using the following 
program: 
Denaturation      95°C    30 s 
Starting temperature   60°C    30 s 
Melting step      60°C     10 s 
                 + 0.5°C per cycle 
 
4.2.3.7  Electrophoretic mobility shift assay (EMSA) 
EMSA was performed as previously described (128). 10 µg nuclear protein (see 4.2.2.2) 
were incubated with 2 µg poly(dIdC), 2 µl buffer D, 4 µl buffer F (see Appendix), and 
250 fmol 5’-IRD700-labelled oligonucleotide in a final volume of 20 µl and incubated 
for 30 min at RT. DNA-protein complexes were resolved at 80 V for approximately 1 h 
using  native  4%  polyacrylamide  gels  and  visualized  with  Odyssey  infrared  imaging 
system.  
4.2.3.8  Construction of the pGL3-PPARγ-3´-UTR 
To assess the impact of PPARγ mRNA stability, its 3´-UTR was cloned into the pGL3-
control vector showing constitutive luciferase expression. Therefore, the 3´-UTR was 
35-45 
cycles 
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amplified by PCR and introduced downstream of the luciferase encoding region of the 
pGL3-control vector using In-Fusion™ Dry-Down PCR cloning Kit. The method is based 
on a recombination process performed by the In-Fusion enzyme.  
Amplification of the insert 
The 3´-UTR was amplified by PCR (see 4.2.3.5) using the primer pair PPARγ-UTR listed 
in  Table  4.6.  The  primer  pair  contains  15  bp  extensions  on  both  sides,  which  are 
complementary to the flanking regions of the XbaI restriction site of the vector. The 
amplification was performed using 5 µl of cDNA from differentiated THP-1 cells. The 
fragment  size  and  DNA  content  was  verified  by  agarose  gel  electrophoresis  (1.5% 
agarose in 0.5 x TBE).  
Insertion of the PCR fragment into the vector 
The  vector  pGL3-control  was  transformed  in  SCS110  bacteria  to  generate 
unmethylated DNA, which was linearized with the restriction enzyme XbaI. Therefore 
1 µg of unmethylated pGL3-control were mixed with 10 U of XbaI, 2.5 µl 10 x reaction 
buffer (NEBuffer 2), filled up to 25 µl with distilled H2O and incubated at 37°C for 1 h. 
For inactivation of the endonuclease, incubation was continued at 65°C for 20 min. 
Subsequently, linearization of the vector was checked by agarose gel electrophoresis 
(1% agarose in 0.5 x TBE). Finally, the pellet of the In-Fusion™ Dry-Down PCR cloning 
Kit was solved with 10 µl distilled H2O containing 1 µl of the restriction probe and 2 µl 
of PCR probe and incubated at 42°C for 30 min. Subsequently, 1 µl of the solution was 
transformed into XL-1 Blue competent bacteria by heat shock method (see 4.2.4.1). 
From potential positive clones plasmids were extracted and digested with Bpn10I and 
NcoI  to  check  insertion  of  the  UTR  fragment.  Correct  insertion  was  verified  by 
sequencing (Agowa GmbH, Berlin).  
4.2.3.9  Site directed mutagenesis for generation of point mutations or deletions 
Site-directed  mutagenesis  for  generation  of  point  mutations  or  deletions  was 
performed  using  the  QuikChange  XL  II  site-directed  mutagenesis  kit.  For  point 
mutation of K77 and S82 within PPARγ1, pDsRed-PPARγ1 was used as a template. For 
deletion  of  the  miR-27  binding  site  within  the  PPARγ-3’-UTR,  pGL3-PPARγ-3’-UTR 
provided the basis. Oligonucleotides were designed according to the manufacturer’s 
specifications  and  listed  in  Table  4.6.  10 ng  of  the  template  DNA,  125 ng  of  each Material and Methods    46 
primer, 5 µl 10 x reaction buffer, 1 µl dNTP mix, 3 µl QuikSolution reagent and 1 µl 
PfuUltra HF DNA polymerase were mixed together and filled up with distilled H2O to 
50 µl. An initial denaturation step was performed at 95°C for 1 min, followed by 18 
cycles of denaturation at 95°C for 50 s and annealing and extension at 68°C for 8 min. 
A final extension phase was performed at 68°C for 10 min. Next, the non-mutated 
parental DNA template was digested with 10 U DpnI for 2 h at 37°C and plasmids were 
transformed into XL10-Gold ultracompetent bacteria using the heat shock method (see 
4.2.4.1).  From  potential  positive  clones  plasmids  were  prepared  and  verified  by 
digestion and finally sequencing (Agowa GmbH, Berlin).  
4.2.4  Microbiology 
4.2.4.1  Transformation of bacteria by heat-shock 
Bacteria  were  transformed  with  plasmid  DNA  by  heat-shock.  Therefore,  50  µl  of 
bacteria  glycerol  stocks  were  thawed  on  ice,  50  ng  plasmid  DNA  were  added  and 
incubated  for  30 min  on  ice.  After  a  heat-shock  for  45  s  at  42°C,  bacteria  were 
incubated for another 2 min on ice. For initial growth, 450 µl of SOC medium (see 
Appendix)  were  added  followed  by  an  incubation  period  for  45  min  at  37°C  with 
shaking at 250 rpm. Depending on the prior experiment, 100-500 µl were inoculated 
on  a  LB  agar  plate  containing  the  appropriate  antibiotic  (100 µg/ml  ampicillin  or 
50 µg/ml  kanamycin)  and  incubated  over  night  at  37°C  to  select  positive,  plasmid 
carrying bacteria clones.  
4.2.4.2  Bacterial culture and plasmid preparation 
For  preparation  of  plasmids  a  single  clone  from  the  LB  agar  plate  was  picked, 
transferred into 3 ml LB medium with the appropriate antibiotic and cultured over 
night at 37°C with shaking (250 rpm). The next day, the culture was transferred into 
200 ml LB medium containing the appropriate antibiotic and again shaked over night at 
37°C. Isolation of plasmids was performed according to the manufacturer’s protocol 
using the HiSpeed Plasmid Maxi Kit. DNA content was measured with the NanoDrop 
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4.2.5  Statistical analysis 
Each experiment was performed at least three times and statistical analysis was done 
either with one- or two-way-ANOVA modified with Bonferroni’s multiple comparison 
test  or  unpaired  and  paired  Student’s  t-test,  respectively.  *p < 0.05,  **p < 0.01, 
***p < 0.001 
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ession of PPARγ1 wild-type in d/n PPARγ macrophages restored 
the  inhibitory  potential  of  AC  on  NFκB  transactivation,  which  was  comparable 
regarding to control cells (Figure 5.4 A). 
To further strengthen the role of PPARγ, RAW264.7 cells were pre
µM GW9662, a specific PPARγ antagonist (164). Thereafter, macrophages were 
AC followed by LPS stimulation as described above. GW9662 completely 
abrogated  the  ability  of  AC  to  attenuate  NFκB  reporter  activity  (
dependent blocking of NFκB transactivation in response to AC. 
To elucidate the functional consequence of NFκB inhibition, I analyzed the expression 
inflammatory, established NFκB target genes such as TNFα (165)
in macrophages treated with AC and LPS. Therefore, I determined IL
PCR in RAW264.7 and RAW264.7 d/n PPARγ macrophages. Cells were c
incubated with AC for 90 min and treated with 1 µg/ml LPS for 3
time period was chosen, because mRNA should appear earlier than luciferase protein. 
dependent reduction of cytokine expression.  
6 mRNA expression were measured by qPCR in RAW264.7 and RAW264.7 
d/n PPARγ cells. Macrophages were co-incubated with AC for 90 min (ratio 1:5) and treated 
afterwards. As a control, macrophages were stimulated with LPS alone 
and relative mRNA expression was set to 1. Data were normalized to GAPDH mRNA levels.
mean values ± SE (n ≥ 5) and statistics were analyzed with two
Bonferroni’s multiple comparison test. 
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cells were pre-stimulated for 3 h 
, macrophages were 
AC followed by LPS stimulation as described above. GW9662 completely 
NFκB  reporter  activity  (Figure  5.4  B), 
transactivation in response to AC.  
To elucidate the functional consequence of NFκB inhibition, I analyzed the expression 
(165) and IL-6 (166) 
in macrophages treated with AC and LPS. Therefore, I determined IL-6 and TNFα mRNA 
d/n PPARγ macrophages. Cells were co-
µg/ml LPS for 3 h afterwards. This 
mRNA should appear earlier than luciferase protein.  
 
PCR in RAW264.7 and RAW264.7 
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ol, macrophages were stimulated with LPS alone 
and relative mRNA expression was set to 1. Data were normalized to GAPDH mRNA levels. 
tatistics were analyzed with two-way-ANOVA Results 
In response to LPS, mRNA expression of TNFα and IL
compared to unstimulated cells and this response was set to a relative mRNA increase 
of 1 (Figure 5.5). Recognition of AC by RAW264.7 macrophages prior to 
reduced TNFα expression by roughly 60% (
was diminished by 90% (
To substantiate a role of PPARγ, experiments were also performed in RAW264.7
PPARγ macrophages. Pre
TNFα  expression  (Figure 
(Figure 5.5 B), thus underscoring the impact of PPARγ on NFκB target gene expression. 
To  verify  the  physiological  significance  of  PPAR
response, I analyzed TNF
(Control) and myeloid lineage
KO). Enriched CD11b
+ splenocytes were differentiated with 25
out  of  PPARγ  was  proven  by  quantif
reduced  in  PPARγ-deficient  macrophages  by  90%  (
differentiation, macrophages were treat
 
Figure 5.6 PPARγ-deficient macrophages impaired
(A)  PPARγ-exon  2  mRNA  expression  and  (B
macrophages from PPARγ
were measured by qPCR. Cells were stimulated 
values  ±  SE  (n  =  5)  and  s
Bonferroni’s multiple compa
 
In response to LPS, mRNA expression of TNFα and IL-6 was at least 50
compared to unstimulated cells and this response was set to a relative mRNA increase 
Recognition of AC by RAW264.7 macrophages prior to 
reduced TNFα expression by roughly 60% (Figure 5.5 A), while IL-6 mRNA expression 
was diminished by 90% (Figure 5.5 B). 
To substantiate a role of PPARγ, experiments were also performed in RAW264.7
PPARγ macrophages. Pre-treating cells with AC, followed by LPS stimulation restored 
Figure  5.5  A)  and  largely  reversed  suppressed  formation  of  IL
thus underscoring the impact of PPARγ on NFκB target gene expression. 
To  verify  the  physiological  significance  of  PPARγ  during  the 
response, I analyzed TNFα mRNA levels in primary murine macrophages from PPAR
(Control) and myeloid lineage-specific conditional PPARγ knock-out
splenocytes were differentiated with 25 ng M-
was  proven  by  quantifying  PPARγ-exon 2  mRNA  amount,  which  was 
deficient  macrophages  by  90%  (Figure  5.6  A
differentiation, macrophages were treated with AC and LPS as described before.
deficient macrophages impaired attenuated TNFα mRNA expression
2  mRNA  expression  and  (B)  TNFα  mRNA  expression  in  primary  murine 
macrophages from PPARγ
fl/fl (Control) and conditional PPARγ knock-out mice (M
PCR. Cells were stimulated with AC and LPS as before
and  statistics  were  analyzed  with  two-way-ANOVA  modified  with 
le comparison test. 
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6 was at least 50-fold increased 
compared to unstimulated cells and this response was set to a relative mRNA increase 
Recognition of AC by RAW264.7 macrophages prior to LPS stimulation 
6 mRNA expression 
To substantiate a role of PPARγ, experiments were also performed in RAW264.7 d/n 
treating cells with AC, followed by LPS stimulation restored 
A)  and  largely  reversed  suppressed  formation  of  IL-6 
thus underscoring the impact of PPARγ on NFκB target gene expression.  
  anti-inflammatory 
mRNA levels in primary murine macrophages from PPARγ
fl/fl 
out mice (MФ-PPARγ 
-CSF for 5 d. Knock-
exon 2  mRNA  amount,  which  was 
A).  Following  their 
ed with AC and LPS as described before.  
 
attenuated TNFα mRNA expression.  
)  TNFα  mRNA  expression  in  primary  murine 
mice (MФ-PPARγ KO) 
with AC and LPS as before. Data are mean 
ANOVA  modified  with Results    54 
Recognition  of  AC  diminished  LPS-induced  TNFα  expression  by  roughly  80%.  This 
reduction was significantly mitigated in PPARγ knock-out macrophages (Figure 5.6 A), 
giving  evidence  for  a  PPARγ-dependent  anti-inflammatory  phenotype  switch  in 
response to AC. 
5.1.3  Identification of PPARγ domains required for NFκB inhibition  
Next, I was interested in elucidating the underlying molecular mechanism. This was 
accomplished  by  NFκB  reporter  assays  in  RAW264.7 d/n  PPARγ  macrophages over-
expressing various deletion constructs of DsRed-tagged PPARγ1, that were previously 
verified  for  their  expression  by  Western  analysis  (81  and  unpublished  data).  The 
DsRed-PPARγ1 wild-type encoding vector was included as a control. As expected, over-
expression of DsRed-PPARγ1 wild-type restored NFκB inhibition in response to AC in 
comparison to RAW264.7 d/n PPARγ macrophages (Figure 5.7).  
 
 
Figure 5.7 Domain analysis of PPARγ.  
(A)  Scheme  of  the  used  deletion  constructs.  (B)  NFκB  reporter  activity  was  measured  in 
RAW264.7 d/n PPARγ cells over-expressing deletion constructs of pDsRed-PPARγ1 as indicated. 
Cells were co-transfected with pNFκB-Luc. Reporter activity was measured after co-incubation 
with AC for 90 min followed by stimulation with 1 µg/ml LPS for 5 h. As a control, cells were 
stimulated with LPS alone and values set to 1. Columns present mean values ± SE, n ≥ 3. 
Statistics were analyzed with two-way-ANOVA modified with Bonferroni’s multiple comparison 
test. 
Over-expression  of  DsRed-PPARγ1-Δaa32-250  failed  to  restore  the  ability  of  AC  to 
inhibit NFκB transactivation, comparable to the situation seen in RAW264.7 d/n PPARγ Results    55 
cells. Amino acids 32-250 of PPARγ span a region of the ligand-independent activation 
domain AF1, the DNA binding domain and a part of the hinge domain. From this results 
I concluded that besides the AF2 domain, responsible for ligand-binding, amino acids 
within the region 32-250 are required for NFκB inhibition.  
Next I observed that over-expression of DsRed-PPARγ1-Δaa309-319, a PPARγ deletion 
construct lacking a region that appears important for co-factor binding (167, 168), 
restored NFκB inhibition (Figure 5.7). These data suggest that amino acids 309-319, 
within the ligand-binding domain, are dispensable for blocking NFκB transactivation in 
response to AC. Moreover, deletion of the aa1-31 also failed to restore NFκB activity, 
assuming that they are not implicated in the AC-provoked repression, whereas amino 
acids  32-250  seem  to  play  a  role.  Considering  that  SUMOylation  of  PPARγ  and 
concomitant  prevention  of  NCoR  removal  is  a  postulated  mechanism  for 
transrepression,  I  analyzed  protein  motives  in  silico  and  noticed  a  possible 
SUMOylation  site  (KXE)  at  K77  within  the  AF1  domain.  Therefore,  I  reasoned  that 
SUMOylation of PPARγ may contribute to NFκB inhibition.  
5.1.4  SUMOylation of PPARγ prevents co-repressor removal 
Preventing  removal  of  NCoR  from  promoter  regions  of  different  pro-inflammatory 
genes  such  as  iNOS  has  been  described  as  a  mechanism  for  PPARγ-mediated 
transrepression that occurs after SUMOylation of PPARγ (77). Among other proteins, 
HDAC3 is associated to the NCoR co-repressor complex and is crucial for transcriptional 
repression (169).  
In a first approach, I inhibited HDAC3 by treatment with trichostatin A (TSA) to see 
whether  the  NCoR/HDAC3  complex  might  be  involved  in  blocking  NFκB  activity. 
RAW264.7 macrophages were pre-treated with 10 nM TSA 1 h prior to AC addition, 
followed by LPS stimulation and subsequent determination of NFκB reporter activity. 
In the presence of TSA, NFκB was not any longer inhibited by AC, whereas TSA alone 
did not alter the LPS response (Figure 5.8).  
 Results 
Figure 5.8 Trichostatin A rev
NFκB  reporter  activity  was  measured  in  RAW264.7  macrophages  after 
10 nM trichostatin A (TSA
addition of 1 µg/ml LPS for 5
± SE, n = 4. Statistics were analyzed with one
comparison test. 
Although  this  experiment  suggest
unclear whether PPARγ is 
promoter. Taking into consideration that amino acids 32
I reasoned K77 to be SUMOylated
 
Figure 5.9 Interfering with
NFκB reporter activity was measured in RAW264.7 d/n PPARγ cells 
PPARγ1 wild-type or pDsRed
Luc.  Reporter  activity  was  meas
stimulation with 1 µg/ml LPS for 5
values set to 1. Columns present mean values ± SE, n 
way-ANOVA modified with 
 
 
reverses AC-provoked inhibition of NFκB transactivation. 
NFκB  reporter  activity  was  measured  in  RAW264.7  macrophages  after 
TSA) for 1 h, followed by exposure to AC for 90 min and subsequent 
µg/ml LPS for 5 h. LPS-elicited values were set to 1. Columns present mean values 
Statistics were analyzed with one-way-ANOVA modified with Bonferroni’s
Although  this  experiment  suggests  a  HDAC-mediated  NFκB  inhibition,  it  remains 
unclear whether PPARγ is SUMOylated and concomitantly retains NCoR bound at the 
Taking into consideration that amino acids 32-250 are involved (
SUMOylated.  
with SUMOylation of PPARγ restored NFκB inhibition
NFκB reporter activity was measured in RAW264.7 d/n PPARγ cells over
type or pDsRed-PPARγ1-K77R as indicated. Cells were co-transfected with pNFκB
Luc.  Reporter  activity  was  measured  after  co-incubation  with  AC  for  90
µg/ml LPS for 5 h. As a control, cells were stimulated with LPS alone and 
Columns present mean values ± SE, n ≥ 4. Statistics were analyzed with two
ied with Bonferroni’s multiple comparison test.  
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of PPARγ restored NFκB inhibition.  
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incubation  with  AC  for  90 min  followed  by 
h. As a control, cells were stimulated with LPS alone and 
stics were analyzed with two-Results 
To approach this possibility, I mutated the 
PPARγ1 wild-type encoding vector. Experimentally, I performed NFκB reporter assays 
in  RAW264.7 d/n  PPARγ  macrophages  and 
DsRed-PPARγ1 wild-type. Along with my expectations, the K77R
unable  to  restore  NFκB  inhibition  compared  to  DsRed
(Figure 5.9 ).  
Since PIAS1 mediates PPARγ 
abrogate  PPARγ  SUMOylation
expression  in  response  to  AC.  Two 
exposed to AC and LPS as described above and TNFα as well as PIAS1 mRNA levels 
were  determined  by  qPCR.
macrophages transfected  with  control  siRNA.  In  comparison,  PIAS1 
approximately 50% at mRNA level (
to attenuate TNFα mRNA expression (
 
Figure 5.10 Impact of PIAS1 on TNFα expression
Two days after transfection of RAW264.7 macrophages with PIAS1 siRNA or siControl, cells 
were co-incubated with AC for 90
PIAS1 and (B) TNFα mRNA levels 
Columns  present  mean  values  ±  SE,  n 
modified with Bonferroni’s
Silencing PIAS1 did not affect LPS
whereas lowering PPARγ 
anti-inflammatory phenotype shift. 
 
To approach this possibility, I mutated the SUMOylation site (K77R) in the pDsRed
type encoding vector. Experimentally, I performed NFκB reporter assays 
d/n  PPARγ  macrophages  and over-expressed  DsRed
type. Along with my expectations, the K77R-mutated protein was 
unable  to  restore  NFκB  inhibition  compared  to  DsRed-PPARγ1  wild
Since PIAS1 mediates PPARγ SUMOylation (77), I knocked down PIAS1 by siRNA to 
SUMOylation  and  analyzed  its  relevance  in  attenuating  TNFα 
expression  in  response  to  AC.  Two  days  after  transfection,  RAW264.7  cells  were 
AC and LPS as described above and TNFα as well as PIAS1 mRNA levels 
were  determined  by  qPCR.  AC  reduced  LPS-induced  TNFα  formation  in  RAW264.7 
macrophages transfected  with  control  siRNA.  In  comparison,  PIAS1 
approximately 50% at mRNA level (Figure 5.10 A) significantly reduced the ability of AC 
to attenuate TNFα mRNA expression (Figure 5.10 B).  
mpact of PIAS1 on TNFα expression.  
Two days after transfection of RAW264.7 macrophages with PIAS1 siRNA or siControl, cells 
incubated with AC for 90 min, followed by LPS stimulation (1 
mRNA levels were measured by qPCR, the LPS response was se
Columns  present  mean  values  ±  SE,  n  ≥  3.  Statistics  were  analyzed  with  two
Bonferroni’s multiple comparison test. 
not affect LPS-induced TNFα expression compared to basal level, 
lowering PPARγ SUMOylation by silencing PIAS1 attenuates an AC
inflammatory phenotype shift.  
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Two days after transfection of RAW264.7 macrophages with PIAS1 siRNA or siControl, cells 
 µg/ml LPS, 3 h). (A) 
PCR, the LPS response was set to 1. 
stics  were  analyzed  with  two-way-ANOVA 
compared to basal level, 
by silencing PIAS1 attenuates an AC-provoked Results 
Since  SUMOylation  of  PPARγ  by  PIAS1  was  shown  to  prevent  removal  of  the  co
repressor  NCoR  from  pro
siRNA  knock-down  and 
transfected with control siRNA, 
LPS-induced TNFα expression
cells interaction with AC reduced LPS
Knock-down  of  NCoR  by  roughly  50%,  as  determined  by 
significantly reverted TNFα expression (
NCoR during inhibition of 
 
Figure 5.11 Impact of NCoR 
Two days after transfection of RAW264.7 macrophages with NCoR siRNA or siControl, cells 
were co-incubated with AC for 90
NCoR and (B) TNFα mRNA levels were measu
are mean values ± SE, n 
Bonferroni’s multiple comparison test. 
To finally verify that SUMOylated
examined  the  association  of  NCoR  within  the  TNFα  promoter  by  ChIP  analy
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90 min and stimulated with 1
Under control conditions NCoR associated with the NFκB si
whereas it was removed
well  as  d/n  PPARγ  over
 
of  PPARγ  by  PIAS1  was  shown  to  prevent  removal  of  the  co
m  pro-inflammatory  promoters  (75,  77),  I  proved  its  impact  by 
and  analyzed  TNFα  mRNA  expression.  In  comparison  to  cells 
transfected with control siRNA, knock-down of NCoR already reduced the 
induced TNFα expression compared to basal level. In control siR
AC reduced LPS-induced TNFα expression by approximately 50%. 
NCoR  by  roughly  50%,  as  determined  by  qPCR  (
significantly reverted TNFα expression (Figure 5.11 B), arguing for the relevance
inhibition of NFκB-dependent cytokine expression.  
Impact of NCoR on TNFα expression.  
Two days after transfection of RAW264.7 macrophages with NCoR siRNA or siControl, cells 
incubated with AC for 90 min, followed by stimulation with 1 µg/ml LPS for 3
TNFα mRNA levels were measured by qPCR, the LPS response was set to 
n ≥ 4. Statistics were analyzed with two-way-ANOVA modified with 
ple comparison test.  
SUMOylated PPARγ affects the occupancy of NFκB sites by NCoR, I 
examined  the  association  of  NCoR  within  the  TNFα  promoter  by  ChIP  analy
RAW264.7  and  RAW264.7  d/n  PPARγ  macrophages  were  pre-trea
min and stimulated with 1 µg/ml LPS for 1 h afterwards or remained as controls. 
Under control conditions NCoR associated with the NFκB site of the TNFα promoter, 
removed from that promoter region in response to LPS in wild
over-expressing  macrophages  (Figure  5.12
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Two days after transfection of RAW264.7 macrophages with NCoR siRNA or siControl, cells 
µg/ml LPS for 3 h. (A) 
PCR, the LPS response was set to 1. Data 
ANOVA modified with 
PPARγ affects the occupancy of NFκB sites by NCoR, I 
examined  the  association  of  NCoR  within  the  TNFα  promoter  by  ChIP  analysis. 
treated  with  AC  for 
h afterwards or remained as controls. 
te of the TNFα promoter, 
from that promoter region in response to LPS in wild-type as 
12).  In  RAW264.7 Results 
macrophages, NCoR remained bound to the promoter after recognition of AC despite 
LPS-stimulation (Figure 
was cleared from the promoter
(Figure 5.12 B). Densitometric analysis using AIDA Image analyzer proved significance 
for the described effect on NCoR association 
 
Figure 5.12 PPARγ antagonizes the removal of NCoR
Association of NCoR with the κB response element within the TNFα promoter w
ChIP analysis. (A) RAW264.7 and (B
AC  for  90 min  and  1 µg/ml  LPS  for  1
independent experiments. (C
of  NCoR  vs.  input  contro
Bonferroni’s multiple comparison test. 
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described that SUMOylation
phosphorylation  of  a  serine  residue  next  to  the 
reason,  I  pre-treated  RAW264.7  macrophages  with  10
SB203580  (171)  for  1 h  followed  by  stimulation  with  AC  (90
described above and determined NFκB reporter activity.
And indeed, inhibition of 
whereas the LPS response was not significantly 
whether p38 phosphorylates PPARγ, 
 
ages, NCoR remained bound to the promoter after recognition of AC despite 
Figure 5.12 A), whereas in RAW264.7 d/n PPARγ macrophages NCoR 
was cleared from the promoter even in response to AC, followed by LPS stimulation 
Densitometric analysis using AIDA Image analyzer proved significance 
for the described effect on NCoR association (Figure 5.12 C).  
PPARγ antagonizes the removal of NCoR.  
Association of NCoR with the κB response element within the TNFα promoter w
ChIP analysis. (A) RAW264.7 and (B) RAW264.7 d/n PPARγ macrophages were incubated with 
µg/ml  LPS  for  1 h  afterwards.  Data  are  representative  for 
independent experiments. (C) Statistical evaluation of ChIP assays showing the relative amount 
of  NCoR  vs.  input  controls.  Statistics  were  analyzed  with  two-way-ANOVA  modified  with 
multiple comparison test.  
Even  though  I  could  elucidate  the  underlying  molecular  mechanism
, it remained so far unclear how PPARγ is SUMOylated
SUMOylation of PPARγ2 in adipocytes is accompanied with subsequent 
phosphorylation  of  a  serine  residue  next  to  the  SUMOylation  site 
ted  RAW264.7  macrophages  with  10 µM  of  the  p38 
h  followed  by  stimulation  with  AC  (90 min)  and  LPS  (5
described above and determined NFκB reporter activity.  
And indeed, inhibition of p38 reversed the potential of AC to repress NFκB activation,
whereas the LPS response was not significantly altered (Figure 5.13
whether p38 phosphorylates PPARγ, I performed a reporter assay in RAW264.7 d/n 
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ages, NCoR remained bound to the promoter after recognition of AC despite 
A), whereas in RAW264.7 d/n PPARγ macrophages NCoR 
in response to AC, followed by LPS stimulation 
Densitometric analysis using AIDA Image analyzer proved significance 
 
Association of NCoR with the κB response element within the TNFα promoter was analyzed by 
) RAW264.7 d/n PPARγ macrophages were incubated with 
h  afterwards.  Data  are  representative  for  three 
) Statistical evaluation of ChIP assays showing the relative amount 
ANOVA  modified  with 
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is accompanied with subsequent 
site  (170).  For  this 
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p38 reversed the potential of AC to repress NFκB activation, 
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reporter assay in RAW264.7 d/n Results 
PPARγ macrophages over
to  DsRed-PPARγ1  wild-
NFκB inhibition in response to AC, excluding phosphorylation of PPARγ at S82 during 
the AC-provoked anti-inflammatory response (
 
Figure 5.13 p38-dependent NFκB 
(A) RAW264.7 cells were treated with 10 µM SB203580 for 1
(1 µg/ml, 5 h). NFκB reporter activity was measured. 
in RAW264.7 d/n PPARγ cells 
S82A. After transfection, cells were 
1. Data present mean values 
On account of this, I concluded that
the  activity  of  NFκB  via  NCoR,  which  contributes  to  immune
macrophages. Moreover, p38 seems to be involved during inhibit
detailed signaling remains unclear. 
5.2  Regulation of PPARγ 
My data of the first part 
macrophages  and  resolution  of  inflammation
molecule  it  seems  likely  that  it  is  tightly  regulated 
immune response. There is growing evidence
inflammation and remarkably, several chronic inflammatory diseases were associated 
with  an  impaired  PPARγ  expression.  Still,  signaling  pathways  re
 
PPARγ macrophages over-expressing PPARγ with a mutated S82 (S82A)
-type,  over-expression  of  DsRed-PPARγ1-S82A  also  restored 
NFκB inhibition in response to AC, excluding phosphorylation of PPARγ at S82 during 
inflammatory response (Figure 5.13 B).  
dependent NFκB inhibition in response to AC.  
RAW264.7 cells were treated with 10 µM SB203580 for 1 h followed by AC (
NFκB reporter activity was measured. (B) NFκB reporter activity was 
in RAW264.7 d/n PPARγ cells over-expressing pDsRed-PPARγ1 wild-type or 
After transfection, cells were treated with AC and LPS as before. LPS values were set to 
present mean values ± SE, n ≥ 4. Statistics were analyzed with one-
On account of this, I concluded that PPARγ SUMOylation in response to AC regulates 
the  activity  of  NFκB  via  NCoR,  which  contributes  to  immune
Moreover, p38 seems to be involved during inhibition of NFκB, whereas 
detailed signaling remains unclear.  
Regulation of PPARγ expression during the inflammatory response
My data of the first part corroborate the eminent role of PPARγ during polarization of 
macrophages  and  resolution  of  inflammation.  As  an  anti-inflammatory  signaling 
it  seems  likely  that  it  is  tightly  regulated dependent  on
There is growing evidence that PPARγ expression is reduced during 
inflammation and remarkably, several chronic inflammatory diseases were associated 
with  an  impaired  PPARγ  expression.  Still,  signaling  pathways  re
60 
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(B) NFκB reporter activity was determined 
type or pDsRed-PPARγ1-
LPS values were set to 
-way-ANOVA. 
in response to AC regulates 
the  activity  of  NFκB  via  NCoR,  which  contributes  to  immune  modulation  of 
on of NFκB, whereas 
during the inflammatory response 
during polarization of 
inflammatory  signaling 
dependent  on the  state  of  the 
that PPARγ expression is reduced during 
inflammation and remarkably, several chronic inflammatory diseases were associated 
with  an  impaired  PPARγ  expression.  Still,  signaling  pathways  reducing  PPARγ Results 
expression are ill-defined. 
mechanisms of PPARγ reduction 
LPS.  
5.2.1  PPARγ1  expression 
exposure 
In the last years, the number of described promoters for differ
variants was nearly doubled, 
(39, 41). Macrophages predominantly express PPARγ1, which was postulated to be 
under the control of promot
levels  of  the  different  transcript  variants  during  differentiation  of  primary  human 
monocytes. Therefore mRNA was extracted from monocyt
3 d and 7 d after isolation from buffy coats
1 µg/ml LPS for 3 h at each time point.
determined  by  qPCR  using  specific 
transcript variant 1 or 3, reverse: PPARγ exon 1)
 
Figure 5.14 Differential expression 
Primary human monocytes were isolated from 
periods for differentiation into macrophages. 
were  stimulated  with  1  µg/ml  LPS  or  left  untreated. 
transcript variants were determined by qPCR. 
analyzed using unpaired Student’s t
 
defined. Therefore, I was interested in elucidating the underlying 
mechanisms of PPARγ reduction in response to the classical pro-inflammatory stimulus 
expression  during  monocyte  differentiation
In the last years, the number of described promoters for different PPARγ transcript 
variants was nearly doubled, even though three transcript variants are well established
. Macrophages predominantly express PPARγ1, which was postulated to be 
under the control of promoter 1 and 3 (54). As a start, I investigated the expression 
levels  of  the  different  transcript  variants  during  differentiation  of  primary  human 
Therefore mRNA was extracted from monocytes/macrophages at 1
d after isolation from buffy coats, which were additionally
h at each time point. Expression of transcript variants 1 and 3 
PCR  using  specific  primer  pairs  (see  Table  4.6
transcript variant 1 or 3, reverse: PPARγ exon 1).  
Differential expression of PPARγ during monocyte/macrophage 
Primary human monocytes were isolated from buffy coats and cultured for increasing time 
periods for differentiation into macrophages. At each time point, monocytes/macrophages 
1  µg/ml  LPS  or  left  untreated.  RNA  levels  of  the  different  PPARγ 
transcript variants were determined by qPCR. Data are mean values ± SE, n =
unpaired Student’s t-test. 
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. Macrophages predominantly express PPARγ1, which was postulated to be 
investigated the expression 
levels  of  the  different  transcript  variants  during  differentiation  of  primary  human 
es/macrophages at 1 h, 1 d, 
, which were additionally stimulated with 
Expression of transcript variants 1 and 3 was 
6,  forward:  PPARγ 
 
monocyte/macrophage differentiation.  
oats and cultured for increasing time 
At each time point, monocytes/macrophages 
RNA  levels  of  the  different  PPARγ 
, n = 3. Statistics were Results 
I predominantly observed induction of the PPARγ transc
and a minor induction of variant 1 after 3
day 7) after full differentiation
(Figure 5.14). 
The reduction of both 
regulation mechanism. Therefore
variant 1 and 3). Time-dependent
1 µg/ml LPS revealed a slight increase after 30
the  lowest  PPARγ1  mRNA  amounts  after  6
periods recovered PPARγ1 mRNA content nearly reaching control levels after 24
LPS treatment (Figure 5
macrophages. As seen in 
PPARγ1 mRNA to approximately 20% in comparison to unstimulated cells.
 
Figure 5.15 Time-dependent reduction of PPARγ
(A) Primary human macrophages were treated with 1
PPARγ1 mRNA levels were determined by qPCR. (B) Differentiated THP
treated with 1 µg/ml LPS for 3
± SE, n ≥ 5. Statistics were performed using
Since  inhibition  of  NFκB  wit
decrease in RAW264.7 macrophages
with 10 µM of the NFκB inhibitor
Inhibition  of  NFκB  significantly  reversed  PPARγ
Moreover, pre-stimulating macrophages with 1
 
predominantly observed induction of the PPARγ transcript variant 3
ion of variant 1 after 3 d (1.3-fold), which was even less
day 7) after full differentiation. Upon LPS exposure both variants were down
 transcript variants upon LPS exposure pointed
Therefore, I further determined total PPARγ1 mRNA
dependent expression analysis of PPARγ1 mRNA in response to 
a slight increase after 30 min followed by a rapid decrease with 
mRNA  amounts  after  6 h  (Figure  5.15  A).  Extended  incubation 
PPARγ1 mRNA content nearly reaching control levels after 24
5.15 A). The same pattern was observed in differentiated THP
macrophages. As seen in Figure 5.15 B, 3 h of LPS exposure significantly decreased 
approximately 20% in comparison to unstimulated cells.
dependent reduction of PPARγ1 mRNA in macrophages. 
Primary human macrophages were treated with 1 µg/ml LPS for different time periods and 
PPARγ1 mRNA levels were determined by qPCR. (B) Differentiated THP-1 macrophages were 
µg/ml LPS for 3 h and PPARγ1 mRNA was measured. Data present mean va
Statistics were performed using unpaired Student’s t-test. 
Since  inhibition  of  NFκB  with  several  inhibitors  prevented  LPS
in RAW264.7 macrophages (172), I pre-treated primary human 
µM of the NFκB inhibitor Bay11-7082 for 1 h followed by LPS exposure
Inhibition  of  NFκB  significantly  reversed  PPARγ1  mRNA  decrease
stimulating macrophages with 1 µM rosiglitazone for 16
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ript variant 3 (10-fold at day 7), 
fold), which was even less (0.58-fold at 
. Upon LPS exposure both variants were down-regulated 
pointed to a common 
PPARγ1 mRNA (transcript 
of PPARγ1 mRNA in response to 
min followed by a rapid decrease with 
Extended  incubation 
PPARγ1 mRNA content nearly reaching control levels after 24 h of 
A). The same pattern was observed in differentiated THP-1 
LPS exposure significantly decreased 
approximately 20% in comparison to unstimulated cells.  
 
mRNA in macrophages.  
µg/ml LPS for different time periods and 
1 macrophages were 
Data present mean values 
LPS-mediated  PPARγ 
primary human macrophages 
owed by LPS exposure for 3 h. 
mRNA  decrease  (Figure  5.16). 
µM rosiglitazone for 16 h prior to 3 h Results 
of LPS also restored PPARγ1 mRNA expression, suggesting that this is due to inhibited 
NFκB  activity  as  well.  Alternatively  to  LPS,  I  further  treated  cells  with  the  pro
inflammatory  cytokines  TNFα  (5  ng/ml)  or  IFNγ  (10  U/ml)  for  3
PPARγ1 mRNA expression.
 
Figure 5.16 NFκB-dependent PPARγ1 mRNA 
Primary  human  macrophages  were 
rosiglitazone  for  16 h  followed  by  3
stimulated with 5 ng/ml TNFα or 10
qPCR. Columns present mean values ± SE, n
Student’s t-test.  
TNFα also attenuated PPARγ1 mRNA even though to a lower extent than LPS. IFNγ 
rather induced mRNA expression (
NFκB activation, I suggested
investigation of mRNA decay upon LPS exposure. 
To check whether the LPS
analyzed protein expression and PPARγ activity by reporter assay.
showed a time-dependent reduction of protein expression with 
again increasing afterwards (
differentiated THP-1 macrophages with the PP
treated cells the next day with 1
rosiglitazone for 4 h. Rosiglitazone, a well described synthetic PPARγ agonist 
induced  luciferase  expression,  whereas  pre
 
of LPS also restored PPARγ1 mRNA expression, suggesting that this is due to inhibited 
ll.  Alternatively  to  LPS,  I  further  treated  cells  with  the  pro
inflammatory  cytokines  TNFα  (5  ng/ml)  or  IFNγ  (10  U/ml)  for  3 
PPARγ1 mRNA expression. 
 
dependent PPARγ1 mRNA decrease.  
Primary  human  macrophages  were  pre-treated  with  10  µM  Bay11-7082  for  1
h  followed  by  3 h  of  LPS  (1 µg/ml).  Alternatively  to  LPS  cells  were 
ng/ml TNFα or 10 U/ml IFNγ. PPARγ1 mRNA amount was determ
s present mean values ± SE, n ≥ 5. Statistics were performed
TNFα also attenuated PPARγ1 mRNA even though to a lower extent than LPS. IFNγ 
expression (Figure 5.16). Since TNFα but not IFNγ
I suggested an analogous molecular mechanism and
A decay upon LPS exposure.  
the LPS-mediated decrease of mRNA is reflected at protein level, I 
analyzed protein expression and PPARγ activity by reporter assay.
dependent reduction of protein expression with a minimum at 8
afterwards (Figure 5.17 A). To determine PPARγ activity, 
1 macrophages with the PPRE reporter plasmid pAOX
treated cells the next day with 1 µg/ml LPS for 6 h followed by stimulation with 5
h. Rosiglitazone, a well described synthetic PPARγ agonist 
induced  luciferase  expression,  whereas  pre-stimulation  with  LPS  prevented 
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of LPS also restored PPARγ1 mRNA expression, suggesting that this is due to inhibited 
ll.  Alternatively  to  LPS,  I  further  treated  cells  with  the  pro-
 h  and  determined 
7082  for  1 h  or  1  µM 
Alternatively  to  LPS  cells  were 
U/ml IFNγ. PPARγ1 mRNA amount was determined by 
Statistics were performed using unpaired 
TNFα also attenuated PPARγ1 mRNA even though to a lower extent than LPS. IFNγ 
but not IFNγ also triggers 
molecular mechanism and focused on the 
decrease of mRNA is reflected at protein level, I 
analyzed protein expression and PPARγ activity by reporter assay. Western analysis 
a minimum at 8 h, 
A). To determine PPARγ activity, I transfected 
RE reporter plasmid pAOX-TK and pre-
h followed by stimulation with 5 µM 
h. Rosiglitazone, a well described synthetic PPARγ agonist (173), 
stimulation  with  LPS  prevented Results 
transactivation  of  PPARγ 
activity (Figure 5.17 B).  
 
Figure 5.17 Time-dependent decrease of PPARγ protein in response to LPS 
(A)  PPARγ  protein  was  determined  by  Western  analysis  after  treating  primary 
macrophages with 1 µg/ml LPS for the indicated time 
measured in differentiated THP
by  5  µM  rosiglitazone  for  4
analyzed with unpaired Student’s
As described before, mRNA decrease can either result from transcriptional or post
transcriptional regulation. T
reduced transcription, I 
(pGL3-γ1p3000) and 3 (pGL3
upstream of the luciferase encoding region. 
Therefore, THP1-macrophages were
and stimulated with 1 µg/ml LPS for 3 and 6
PPARγ  promoter  1  luciferase  activity  to  approximately  60%  after  6
luciferase activity of the PPAR
(Figure  5.18).  Taking  into  consideration  that  during  differentiation  of  macrophages 
promoter 1 was only slightly induced
promoter 1 activity to 60% is negligible for the LPS
Thus,  I  hypothesized that 
regulation.  
 
 
of  PPARγ  by  rosiglitazone.  LPS  alone  did  not  alter  basal  luciferase 
 
dependent decrease of PPARγ protein in response to LPS 
(A)  PPARγ  protein  was  determined  by  Western  analysis  after  treating  primary 
µg/ml LPS for the indicated time points. (B) PPRE reporter activity was 
measured in differentiated THP-1 macrophages after pre-treatment with LPS
by  5  µM  rosiglitazone  for  4 h.  Columns  present  mean  values  ±  SE,  n 
Student’s t-test.  
mRNA decrease can either result from transcriptional or post
transcriptional regulation. To determine whether PPARγ1 mRNA decrease was due to 
 performed luciferase reporter assays using PPARγ promoter 1 
γ1p3000) and 3 (pGL3-γ3p800) constructs, containing the individual promoters 
upstream of the luciferase encoding region.  
macrophages were transfected with pGL3-γ1p3000 or pGL3
µg/ml LPS for 3 and 6 h the following day. LPS exposure lowered 
promoter  1  luciferase  activity  to  approximately  60%  after  6
luciferase activity of the PPARγ promoter 3 construct was not significantly reduced
Taking  into  consideration  that  during  differentiation  of  macrophages 
only slightly induced (see Figure 5.14), I assumed that reduction of the 
promoter 1 activity to 60% is negligible for the LPS-induced PPARγ
that  the  mRNA decrease is  rather due  to post
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by  rosiglitazone.  LPS  alone  did  not  alter  basal  luciferase 
 
dependent decrease of PPARγ protein in response to LPS  
(A)  PPARγ  protein  was  determined  by  Western  analysis  after  treating  primary  human 
points. (B) PPRE reporter activity was 
treatment with LPS for 6 h followed 
,  n  ≥  4.  Statistics  were 
mRNA decrease can either result from transcriptional or post-
decrease was due to 
performed luciferase reporter assays using PPARγ promoter 1 
γ3p800) constructs, containing the individual promoters 
γ1p3000 or pGL3-γ3p800 
day. LPS exposure lowered 
promoter  1  luciferase  activity  to  approximately  60%  after  6 h,  whereas 
promoter 3 construct was not significantly reduced 
Taking  into  consideration  that  during  differentiation  of  macrophages 
that reduction of the 
induced PPARγ1 mRNA decrease. 
post-transcriptional Results 
Figure 5.18 Impact of LPS on 
THP-1 macrophages were transfected with PPARγ 
with 1 µg/ml LPS for 3 and 6
Each measuring point represents the mean value of duplicate determinations of a minimum of 
three  independent  experiments.  Statistics  were  analyzed  using 
whereas reduction was only significant
5.2.2  Post-transcriptional regulation of PPARγ1 mRNA
Altered  mRNA  half-life  is  a  common  mechanism  regulating  gene  expression  and  is 
responsible for reduced mRNA amounts. For this reason, 
by  exposing  cells  to  LPS  and/or  the  transcription  inhibitor  5
ribofuranosylbenzimidazole  (DRB) 
expression  to  approximately  60%  after  3
decreased mRNA to 26% in comparison to untreated cells
 
Figure 5.19 Altered mRNA half
Primary  human  macrophages  were  exposed  to  10
benzimidazole (DRB, squares and black solid line)
trend line) for 1 and 3 h 
values ± SE, n ≥ 4. Statistics were analyzed with 
 
 
act of LPS on PPARγ promoter activity.  
1 macrophages were transfected with PPARγ 1 and 3 promoter constructs, 
3 and 6 h. Luciferase activity was normalized to protein concentration. 
represents the mean value of duplicate determinations of a minimum of 
three  independent  experiments.  Statistics  were  analyzed  using  unpaired 
tion was only significant (p = 0.03) for PPARγ 1 promoter activity.
criptional regulation of PPARγ1 mRNA 
life  is  a  common  mechanism  regulating  gene  expression  and  is 
responsible for reduced mRNA amounts. For this reason, I determined mRNA stability 
by  exposing  cells  to  LPS  and/or  the  transcription  inhibitor  5
ribofuranosylbenzimidazole  (DRB)  (174).  DRB  treatment  reduced  PPARγ
expression  to  approximately  60%  after  3 h,  whereas  a  DRB  plus  LPS  exposure 
decreased mRNA to 26% in comparison to untreated cells (Figure 5.19
 
A half-life upon LPS exposure.  
Primary  human  macrophages  were  exposed  to  10 µM  5–6  dichloro
squares and black solid line) or DRB plus 1 µg/ml LPS 
 and PPARγ1 mRNA was determined by qPCR.
Statistics were analyzed with unpaired Student’s t-test. 
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promoter constructs, stimulated 
. Luciferase activity was normalized to protein concentration. 
represents the mean value of duplicate determinations of a minimum of 
unpaired  Student’s  t-test, 
1 promoter activity. 
life  is  a  common  mechanism  regulating  gene  expression  and  is 
mined mRNA stability 
by  exposing  cells  to  LPS  and/or  the  transcription  inhibitor  5–6  dichloro-1-β-
.  DRB  treatment  reduced  PPARγ1  mRNA 
h,  whereas  a  DRB  plus  LPS  exposure 
19).  
6  dichloro-1-β-ribofuranosyl-
 (triangle and dashed 
. Data present mean 
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Calculating the half-life (t
3.0 h. Interrupted transcription by 
Destabilization is mostly 
degradation. Hence, I analyzed the PPARγ
3’UTR with various ARE sites and a miR
PPARγ-3’UTR contains three ARE1 sites (AUUUA) and one ARE4 site (12
maximal one mismatch) (
 
Figure 5.20 Sequence of the AU
The miR-27 binding site is 
ARE4 (12-mer A/U with max. one mismatch) sites are marked with boxes.
To  prove  the  hypothesis  that  PPARγ
investigated  the  effect
Therefore,  the  3’UTR  was  inserted 
within  the  pGL3-control  vector
luciferase  encoding  region.  Therewith,  cells  transfected  with  pGL3
constitutively express luciferase. 
Differentiated THP-1 cells were transfected with pGL3
respectively, and stimulated with LPS for 3 and 6
reduced luciferase activity 
50%  after 6 h  in  comparison to pGL3
luciferase  activity  of  pGL3
importance of the PPARγ
 
 
 
life (t ½) of PPARγ1 by extrapolation revealed a 
. Interrupted transcription by DRB plus LPS reduced t ½ to 1.93 
mostly due to AU-rich 3’UTRs, which targets mRNAs for cytoplasmic 
analyzed the PPARγ1 mRNA sequence and noticed an AU
3’UTR with various ARE sites and a miR-27 binding site. Referring to Shavora 
3’UTR contains three ARE1 sites (AUUUA) and one ARE4 site (12
maximal one mismatch) (Figure 5.20). 
Sequence of the AU-rich PPARγ-3’UTR.  
27 binding site is displayed in a green underlined font, whereas ARE1 (AUUUA) and 
er A/U with max. one mismatch) sites are marked with boxes. 
the  hypothesis  that  PPARγ1  mRNA  decrease  is  due  to  destabilization
effect  of  the  PPARγ-3’UTR  on  mRNA  stability  by  reporter  assay. 
was  inserted  downstream  of  the  luciferase  encoding  region 
control  vector,  which  contains  a  SV40-promoter 
luciferase  encoding  region.  Therewith,  cells  transfected  with  pGL3
constitutively express luciferase.  
cells were transfected with pGL3-control and pGL3
respectively, and stimulated with LPS for 3 and 6 h the following day. LPS significantly 
reduced luciferase activity of pGL3-PPARγ-3’UTR to approximately 65% after 3
mparison to pGL3-control.  Figure 5.21 displays the ratio of  the 
luciferase  activity  of  pGL3-PPARγ-3’UTR  vs.  pGL3-control,  demonstrating 
of the PPARγ-3’UTR for mRNA stability. 
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by extrapolation revealed a mRNA half-life of 
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rich 3’UTRs, which targets mRNAs for cytoplasmic 
ce and noticed an AU-rich 
Referring to Shavora et al. the 
3’UTR contains three ARE1 sites (AUUUA) and one ARE4 site (12-mer A/U with 
 
, whereas ARE1 (AUUUA) and 
 
due  to  destabilization,  I 
3’UTR  on  mRNA  stability  by  reporter  assay. 
of  the  luciferase  encoding  region 
promoter  upstream  of  the 
luciferase  encoding  region.  Therewith,  cells  transfected  with  pGL3-control 
control and pGL3-PPARγ-3’UTR 
day. LPS significantly 
to approximately 65% after 3 h and to 
displays the ratio of  the 
control,  demonstrating  the Results 
Figure 5.21 PPARγ-3’UTR-
Differentiated THP-1 macrophages were transfected with pGL3
and stimulated with LPS 
protein  concentration.  T
measuring  point  represents  mean  value
experiments. Statistics were anal
5.2.3  miR-27b destabilizes
In silico analysis revealed a miR
perfect match to the miR
nucleotides between positions 12
 
Figure 5.22 Impact of the 
(A)  Alignment  of  the  miR
deletion construct pGL3-PPARγ
region is marked with a box,
is displayed in a green underlined 
pGL3-control, pGL3-PPARγ
measured after stimulation with
control transfected cells. Basal a
Statistics were analyzed with paired 
 
 
-dependent reduction of luciferase expression.  
1 macrophages were transfected with pGL3-control or pGL3
with LPS for 3 and 6 h. Luciferase activity was measured and
The  ratio  of  pGL3-PPARγ-3’UTR/pGL3-control  is  displayed.  Each 
measuring  point  represents  mean  values  of  duplicate  determinations  of  five
experiments. Statistics were analyzed using unpaired Student’s t-test. 
destabilizes PPARγ1 mRNA 
analysis revealed a miR-27 binding site within the 3’UTR (Figure 
perfect match to the miR-27a and b seed (positions 1-8) and additional complem
between positions 12-17 (Figure 5.22 A).  
the miR-27 binding site within the 3’UTR.  
(A)  Alignment  of  the  miR-27a/b  sequences  with  the  PPARγ-3’UTR.  (B)  Alignment  of  the 
PPARγ-UTR-ΔmiR-27 with the PPARγ-3’UTR. In (A) and (B), t
region is marked with a box, the ARE1 site is highlighted in grey, while the miR
underlined font (C) Differentiated THP-1 cells were transfec
PPARγ-3’UTR or pGL3-PPARγ-3’UTR-ΔmiR-27 and luciferase expression was 
measured after stimulation with 1 µg/ml LPS for 3 h and displayed in comparison to pGL3
control transfected cells. Basal activity was set to 1. Columns present mean values ± SE, n 
alyzed with paired Student’s t-test. 
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ontrol or pGL3-PPARγ-3’UTR 
uciferase activity was measured and normalized to 
control  is  displayed.  Each 
f  duplicate  determinations  of  five  independent 
Figure 5.20), showing 
and additional complementary 
 
(B)  Alignment  of  the 
In (A) and (B), the seed 
while the miR-27 binding site 
1 cells were transfected with 
27 and luciferase expression was 
in comparison to pGL3-
Columns present mean values ± SE, n ≥ 4. Results 
As  a  first  approach,  I  deleted
vector (Figure 5.22 B) and again measured luciferase activity in transiently transfected 
THP-1 macrophages. Deletion of 
reduction of luciferase activity (
As deletion of the miR-27 site within the 3’UTR points to an involvement of miR
the LPS-mediated decay, I analyzed 
LPS exposure. Therefore, 
PPARγ1 mRNA reduction was already seen after 3
Expression levels were determined
and a 1.6-fold induction of miR
was significantly and miR
to  LPS  alone  (Figure  5.
dependence pointed to the involvement of miR
since decay was also seen to be NFκB
 
Figure 5.23 MiR-27 expression and NFκB dependence. 
(A) MiR-27a and b expression was measured in primary human macrophages in respo
LPS (1 µg/ml, 2 h) by qPCR. To investigate
pre-stimulated with 10 µM Bay11
mean values ± SE, n = 4. Statistics were analyzed with 
To prove this, primary macrophages were transfected with either an anti
miRNA-inhibitor or a miR
were stimulated with 1 
In cells transfected with anti
reversed in comparison to the negative control (
 
As  a  first  approach,  I  deleted  the  miR-27  sequence  within  the  pGL3
B) and again measured luciferase activity in transiently transfected 
Deletion of the miR-27 site completely reversed LPS
luciferase activity (Figure 5.22 C). 
27 site within the 3’UTR points to an involvement of miR
mediated decay, I analyzed miR-27a and b expression in macrophages upon 
LPS exposure. Therefore, cells were stimulated with 1 µg/ml LPS for 2
reduction was already seen after 3 h.  
determined by qPCR. I observed a 2-fold induction of miR
fold induction of miR-27a (Figure 5.23 A). Moreover, induction of miR
was significantly and miR-27b at least in part prevented by Bay11-7082 
.23).  Both  induction of miR-27a/b  and at  least  partial NFκB
dependence pointed to the involvement of miR-27 in PPARγ1 mRNA destabilization, 
since decay was also seen to be NFκB-dependent.  
 
27 expression and NFκB dependence.  
27a and b expression was measured in primary human macrophages in respo
h) by qPCR. To investigate possible a NFκB-dependence, cells were 
stimulated with 10 µM Bay11-7082 for 1 h. Basal expression was set to 1. 
. Statistics were analyzed with unpaired Student’s t
To prove this, primary macrophages were transfected with either an anti
inhibitor or a miR-27a or b mimic, respectively. 48 h after transfection, cells 
 µg/ml LPS for 3 h and PPARγ1 mRNA was determined by qPCR
n cells transfected with anti-miR-27b, LPS-dependent mRNA reduction was partially 
reversed in comparison to the negative control (Figure 5.24 A).  
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27  sequence  within  the  pGL3-PPARγ-3’UTR 
B) and again measured luciferase activity in transiently transfected 
27 site completely reversed LPS-dependent 
27 site within the 3’UTR points to an involvement of miR-27 in 
ession in macrophages upon 
µg/ml LPS for 2 h, since a strong 
fold induction of miR-27b 
Moreover, induction of miR-27a 
7082 in comparison 
27a/b  and at  least  partial NFκB-
γ1 mRNA destabilization, 
27a and b expression was measured in primary human macrophages in response to 
dependence, cells were additionally 
. Basal expression was set to 1. Columns present 
t-test. 
To prove this, primary macrophages were transfected with either an anti-miR-27a or b 
fter transfection, cells 
as determined by qPCR. 
dependent mRNA reduction was partially Results 
Figure 5.24 Effect of miR-27b 
Primary human macrophages were transfected with (A) 
(B) miR-27b mimic or siControl. After transfection, cells were stimulated with 1 µg/ml LPS for 
3 h and PPARγ1 mRNA level was determined by qPCR. Column
n ≥ 4. Statistics were analyzed with paired 
Consequently, transfection with 
not significantly enhanced by further addition of LPS (
In contrast, inhibition of miR
exposure (Figure 5.25 A). 
 
Figure 5.25 Effect of miR-27a on PPARγ
Primary human macrophages were tran
(B) miR-27a mimic or siControl. After transfection, cells were stimulated with 1 µg/ml LPS for 
3 h and PPARγ1 mRNA level was determined by qPCR. Column
n ≥ 4.  
 
27b on PPARγ1 mRNA decay.  
Primary human macrophages were transfected with (A) anti-miR-27b or a
27b mimic or siControl. After transfection, cells were stimulated with 1 µg/ml LPS for 
h and PPARγ1 mRNA level was determined by qPCR. Columns present mean values ± SE, 
4. Statistics were analyzed with paired Student’s t-test. 
Consequently, transfection with a miR-27b mimic reduced PPARγ1
not significantly enhanced by further addition of LPS (Figure 5.24 B). 
inhibition of miR-27a did not affect PPARγ1 mRNA reduction upon LPS 
A).  
27a on PPARγ1 mRNA decay.  
Primary human macrophages were transfected with (A) anti-miR-27a or a n
mimic or siControl. After transfection, cells were stimulated with 1 µg/ml LPS for 
h and PPARγ1 mRNA level was determined by qPCR. Columns present mean values ± SE, 
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27b or a negative control or 
27b mimic or siControl. After transfection, cells were stimulated with 1 µg/ml LPS for 
s present mean values ± SE, 
1 mRNA, which was 
B).  
reduction upon LPS 
 
or a negative control or 
mimic or siControl. After transfection, cells were stimulated with 1 µg/ml LPS for 
s present mean values ± SE, Results 
Transfection with the miR
enforced by the further addition 
miR-27a-dependent  destabilization  of  PPAR
partially reversed PPAR
restored luciferase activity. Since the deleted sequence also 
with one nucleotide overlap to the miR
an  ARE-binding  protein  might  be  involved  additionally  to  miR
macrophages  to  several  inhibitors  might  support  this  assumption. 
dependent  mRNA  decay  can  depend  on  translation, 
cycloheximide (CHX). Pre
PPARγ1 mRNA, whereas the LPS
5.26). Moreover, several ARE
localization. Therefore, 
the  export  receptor  Crm1  (chromosome  maintenance  1)  or  exportin  1,  which  is 
essential  for  nuclear  export  signal
with 50 nM LMB reduced basal expression level and showed a slighter reduction 
PPARγ1 mRNA upon LPS exposure 
least partial involvement of protein export
 
Figure 5.26 Impact of translation and 
Primary human macropha
leptomycin B (LMB) for 1
was determined by qPCR. 
 
Transfection with the miR-27a mimic also reduced PPARγ mRNA, which moreover was 
by the further addition of LPS (Figure 5.25 B), suggesting 
dependent  destabilization  of  PPARγ1  mRNA.  Inhibition  of  miR
partially reversed PPARγ1 mRNA decay, but deletion of the miR-
stored luciferase activity. Since the deleted sequence also contained a
with one nucleotide overlap to the miR-27 binding site (Figure 5.22
binding  protein  might  be  involved  additionally  to  miR
macrophages  to  several  inhibitors  might  support  this  assumption. 
dependent  mRNA  decay  can  depend  on  translation,  I  inhibited  translation  using 
re-treating cells with 10 mg/ml CHX for 1 h significantly induced 
whereas the LPS-dependent decrease seems not to be affected
several ARE-binding proteins are regulated by the c
I blocked nuclear export with leptomycin B (LMB)
the  export  receptor  Crm1  (chromosome  maintenance  1)  or  exportin  1,  which  is 
for  nuclear  export  signal-dependent  transport  (175,  176)
reduced basal expression level and showed a slighter reduction 
ARγ1 mRNA upon LPS exposure in comparison to control cells, thus 
involvement of protein export (Figure 5.26).  
 
Impact of translation and nuclear export on PPARγ1 mRNA decay
ages were pre-treated with 10 mg/ml cycloheximide (CHX) or 50 nM 
leptomycin B (LMB) for 1 h followed by stimulation with 1 µg/ml LPS for 3
was determined by qPCR. Columns present mean values ± SE, n ≥ 3. 
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A, which moreover was 
 a miR-27b- but not 
nhibition  of  miR-27b  only 
-27 site completely 
contained an ARE1 site 
22 B), I assumed that 
binding  protein  might  be  involved  additionally  to  miR-27b.  Exposing 
macrophages  to  several  inhibitors  might  support  this  assumption.  Since  ARE-
I  inhibited  translation  using 
h significantly induced 
to be affected (Figure 
binding proteins are regulated by the control of cellular 
eptomycin B (LMB). LMB inhibits 
the  export  receptor  Crm1  (chromosome  maintenance  1)  or  exportin  1,  which  is 
(175,  176).  Pre-stimulation 
reduced basal expression level and showed a slighter reduction of 
in comparison to control cells, thus suggesting at 
nuclear export on PPARγ1 mRNA decay.  
ted with 10 mg/ml cycloheximide (CHX) or 50 nM 
for 3 h. PPARγ1 mRNA Results    71 
My data support the assumption that LPS destabilizes PPARγ1 mRNA partially by the 
NFκB-dependent  induction  of  miR-27b.  The  ARE1  site  proximate  to  the  miR-27b-
binding site as well as a protein export-dependent mRNA decay point to a further 
involvement of ARE-binding proteins, whereas de-novo synthesis of an ARE-binding 
protein can be excluded.  
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6  Discussion 
Macrophages  play  a  fundamental  role  during  initiation  as  well  as  resolution  of 
inflammation, which is due to distinct macrophage phenotypes. Deficient initiation of 
inflammation  is  as  detrimental  as  deficient  resolution,  while  the  latter  one  often 
causes  the  development  of  chronic  inflammatory  diseases.  On  account  of  this, 
coordination  of  macrophage  phenotypes  during  whole  inflammatory  processes  is 
crucial for tissue homeostasis. In the resolution phase determination of macrophage 
phenotypes is among others dependent on phagocytosis of AC. Removal of AC avoids 
secondary necrosis and actively shifts macrophages towards a regulatory phenotype. 
One  characteristic  of  this  anti-inflammatory  phenotype  is  the  attenuation  of  NFκB 
activity. Underlying mechanisms blocking NFκB transactivation are poorly described, 
thus the aim of my studies was to investigate pathways leading to NFκB inhibition 
focusing on the role of PPARγ in this context.  
PPARγ is well described to suppress release of pro-inflammatory cytokines as well as 
mediators  such  as  NO and  ROS  in  macrophages.  During  initiation  of inflammation, 
activation of PPARγ would rather be harmful by preventing a proper immune response 
whereas during resolution it helps to dampen inflammation. For this reason, it seems 
obvious  that  PPARγ,  as  an  anti-inflammatory  mediator,  is  tightly  regulated  during 
inflammation.  Since,  TZDs  are  already  approved  for  use  in  treatment  of  type-2 
diabetes, PPARγ gained special interest as a target for chronic inflammatory diseases. 
These  diseases  are  often  associated  with  an  impaired  PPARγ  expression,  whereas 
underlying  mechanisms  for  reduction  of  PPARγ  expression  are  poorly  understood. 
Thus,  the  second  part  of  my  thesis  addressed  the  clarification  of  underlying 
mechanisms responsible for PPARγ decrease during inflammation.  
6.1  PPARγ contributes to macrophage polarization in response to AC 
PPARγ  is  well  described  for  its  anti-inflammatory  properties  by  inhibiting  MAPK 
cascades, PKCα activation or by repressing several transcription factors such as NFκB, 
AP-1 or Stat1 (63). Even though, many of these effects were discovered rather by 
treatment with synthetic PPARγ agonists (TZDs) than in physiological processes.  
Recently,  PPARγ  was  implicated  in  macrophage  polarization  provoked  by  IL-4,  the 
classical  stimulus  for  alternative  activation  of  macrophages  (or  wound-healing Discussion    73 
macrophages). Using macrophages from macrophage-specific PPARγ knock-out mice 
revealed that the reduced production of pro-inflammatory cytokines such as IL-6 and 
the  enhanced  expression  of  the  alternative  phenotype  markers  arginase  I  and 
mannose  receptor  are  mediated  by  either  PPARγ-dependent  suppression  or  gene 
induction  (57).  Besides  IL-4,  AC  induce  a  switch  of  macrophages  towards  an  anti-
inflammatory phenotype, although underlying mechanisms are insufficiently clear. I 
provide evidence that PPARγ gets activated and most likely SUMOylated in response to 
AC, which is essential for blocking NFκB transactivation. My basic observation that AC 
attenuate LPS-induced NFκB transactivation is in line with the work of Cvetanovic et 
al., demonstrating a diminished NFκB activity in response to AC (136). The notion that 
PPARγ is activated by AC (128) and well established for inhibition of NFκB (64, 162, 
177),  stimulated  my  interest  in  identifying  underlying  molecular  mechanisms.  I 
followed a molecular and pharmacological approach to establish the contributing role 
of PPARγ by using cells that express a dominant negative (d/n) mutant of PPARγ. This 
mutant carries two amino acid substitutions in the AF2 domain (L466A/E469A) of the 
protein, which impair ligand-dependent PPARγ transactivation and the interaction with 
co-activators,  e.g.  p300  (163).  In  RAW264.7 d/n  PPARγ  macrophages,  inhibition  of 
NFκB in response to AC was completely relieved. As a prove of concept, functionality in 
RAW264.7  d/n  PPARγ  macrophages  was  restored  by  over-expressing  PPARγ1  wild-
type,  which  again  suppressed  NFκB  reporter  activity  in  response  to  AC. 
Pharmacologically, the impact of PPARγ was further corroborated by using GW9662 to 
antagonize  PPARγ,  which  restored  NFκB  reporter  activity  after  adding  AC  to 
macrophages. During these studies, AC were co-cultured with macrophages for 6.5 h, 
which  comprises  a  90 min  lasting  pre-incubation  period  with  AC,  followed  by  LPS 
stimulation for 5 h. During the entire incubation period, AC remained in the medium, 
without removing non-ingested cells. However, removing non-phagocytosed cells after 
30 min  followed  by  LPS  stimulation  failed  to  block  NFκB  activity  in  my  system. 
Variations in the stimulation regimes of macrophages with AC may affect macrophage 
plasticity. Majai et al. observed that a treatment of cells with LPS for 30 min, followed 
by incubations with AC for 25 min and subsequent by removal of non-ingested cells, 
lowered the amount of the NFκB target gene TNFα when measured 18-24 h later (178). 
This response was not antagonized by GW9662. Likely, pro-inflammatory stimuli given Discussion    74 
to macrophages prior to confronting them with AC might activate distinct pathways, 
e.g. receptor desensitization or PPARγ decrease. These pathways contribute to the 
diversity of anti-inflammatory responses, with the further possibility that short vs. long 
incubation periods differ towards the involvement of PPARγ.  
To verify the inhibitory role of PPARγ in my system, I not only followed NFκB reporter 
activity, but also searched for the expression of NFκB downstream target genes, i.e. 
TNFα  and  IL-6.  Their  transcriptional  expression  was  reduced  in  response  to  AC  in 
RAW264.7 and primary murine macrophages. Furthermore, cytokine formation was 
partially restored in the case of IL-6 and fully restored in the case of TNFα, when 
exposing d/n PPARγ cells to AC. Supporting evidence for PPARγ-mediated suppression 
came from experiments in PPARγ knock-out macrophages, where the inhibitory effect 
of AC on NFκB activity was abolished. These data support conclusions by Odegaard et 
al. using macrophages from PPARγ knock-out mice, showing that PPARγ is required for 
attenuation  of  IL-6  expression  by  IL-4  (57).  In  addition,  the  role  of  PPARγ  for 
macrophage polarization was further corroborated by Bouhlel et al., reporting that IL-4 
promotes  an  anti-inflammatory  macrophage  phenotype  by  activating  PPARγ  (179). 
Alternative activation of macrophages by IL-13 also activated PPARγ, in turn generating 
an anti-inflammatory phenotype (180). 
Despite increasing evidence for a role of PPARγ in macrophage polarization, molecular 
mechanisms explaining repression of NFκB, one crucial transcription factor regulating 
the inflammatory repertoire of macrophages by AC are ill-defined. Proposed strategies 
how PPARγ represses NFκB comprise competition with co-activators or inhibition of 
co-repressor clearance (63). I analyzed domains of PPARγ being involved in blocking 
NFκB  transactivation.  DsRed-PPARγ1  wild-type,  DsRed-PPARγ1-Δaa1-31  as  well  as 
DsRed-PPARγ1-Δaa309-319 attenuated NFκB activity in response to AC. Amino acids 1-
31  regulate  cytosolic  translocalization  of  PPARγ  and  concomitant  PKCα  inhibition 
(unpublished data). Thus, missing prevention of NFκB inhibition points to mechanisms 
occurring in the nucleus and hence PKCα-independent. Moreover, considering that 
amino acids 309-319 are required for binding transcriptional co-activators (167, 168) 
ruled out a simple co-activator scavenging of e.g. p300, to explain inhibition of NFκB. 
Cvetanovic  et  al.  postulated  that  reduced  availability  of  p300  is  responsible  for 
inhibited NFκB transactivation, which was due to restored NFκB activity after over-Discussion    75 
expressing p300 (136). Over-expression of co-activators in general might not reflect 
the  specificity  of  transrepression  observed  for  endogenous  occurring  co-activator 
abundance. Moreover, enhanced availability of required co-activators might overcome 
repressive effects occurring by different mechanisms.  
Interestingly,  over-expression  of  DsRed-PPARγ1-Δaa32-250  restored  NFκB 
transactivation, compared to the action of DsRed-PPARγ1 wild-type. Deleted amino 
acids in PPARγ1-Δaa32-250 span a part of the AF1 domain, the DNA binding domain, a 
part  of  the  hinge  domain  and  thus,  contain  a  predicted  SUMOylation  site  at  K77. 
SUMOylation  of  PPARγ  was  shown  to  attenuate  NFκB  target  gene  expression  by 
preventing  NCoR  removal  from  NFκB  binding  sites  in  various  promoter  regions  of 
target  genes  such  as  iNOS  (77).  NCoR  is  a  component  of  a  co-repressor  complex, 
containing TBL1, TBLR1 and HDAC3, the latter one mediating transcriptional repression 
(169). A potential role for the NCoR-associated HDAC3 was proposed when the HDAC 
inhibitor  TSA  reversed  PPARγ-dependent  repression  of  iNOS  (77).  In  analogy,  TSA 
reversed inhibition of NFκB by AC, suggesting that a similar mechanism might operate 
in response to AC. ChIP analysis confirmed that NCoR is cleared from the NFκB site 
within  the  TNFα  promoter  after  LPS  stimulation,  but  remained  bound  when 
macrophages were pre-stimulated with AC. Pascual et al. noticed that SUMOylated 
PPARγ  suppressed  the  NFκB  target  gene  iNOS  (77).  The  model  predicts  that 
NCoR/HDAC3 associates with NFκB binding sites along with TBL1 and TBLR1, which are 
required  for  ubiquitination  of  NCoR  in  response  to  pro-inflammatory  stimuli  (74). 
Following SUMOylation, PPARγ binds to NCoR/HDAC3 and prevents the recruitment of 
the  ubiquitination/19S proteasome  machinery  that  normally  degrades  the  co-
repressor complex. This scenario requires ligand-dependent PPARγ activation and K365 
SUMOylation (77). PPARγ contains two possible SUMOylation sites at K77 and K365 
and  my  experiments  with  the  PPARγ  aa32-250  deletion  fragment  pointed  to  the 
involvement of K77 rather than K365. Indeed, over-expression of DsRed-PPARγ1-K77R 
in  RAW264.7  d/n  PPARγ  cells  failed  to  restore  NFκB  repression,  indicating  that 
SUMOylation  of  PPARg  at  K77  represses  NFκB  transactivation.  Moreover,  this  also 
demonstrates that beside SUMOylation at K77, also ligand-binding is required, since 
the use of the d/n mutant failed to repress NFκB. My studies do not rule out the 
possibility that PPARγ is also SUMOylated at K365, but at least this would not to be Discussion    76 
sufficient for NFκB inhibition under my experimental conditions. Furthermore, knock-
down of the SUMO E3 ligase PIAS1, which mediates PPARγ SUMOylation (77), reversed 
the inhibitory ability of AC. Even though I could not directly show PPARγ SUMOylation, 
it seems very likely, since mutation of the SUMOylation site as well as knock-down of 
the SUMO E3 ligase PIAS1 abrogated NFκB inhibition or TNFα reduction in response to 
AC.  
 
 
Figure 6.1. SUMOylation of PPARγ prevents NCoR removal and concomitant NFκB activation. 
Left panel: LPS binding to the TLR4 complex induces IκB degradation and translocalization of 
NFκB to the nucleus. Upon LPS, NCoR is ubiquitinated and degraded, co-activators can bind 
and  induce  target  gene  transcription.  Right  panel:  Recognition  of  AC  activates  p38  and 
Ubc9/PIAS1,  inducing  SUMOylation  of  PPARγ.  SUMOylated  PPARγ  is  targeted  to  NCoR, 
prevents  its  removal  and  therewith  represses  NFκB  transactivation.  Abbreviations:  AC: 
apoptotic  cells,  IκB:  inhibitor  of  κB,  LPS:  lipopolysaccharide,  NCoR:  nuclear  receptor  co-
repressor,  TLR4:  toll-like  receptor  4,  PIAS1:  protein  inhibitor  of  activated  Stat  1,  PPARγ: 
peroxisome proliferator-activated receptor γ, SUMO: small-ubiquitin related modifier 
However, aiming at molecular mechanisms triggering PPARγ SUMOylation, I found that 
NFκB inhibition was dependent on p38 activation, since pharmacological inhibition of Discussion    77 
p38 restored NFκB activity. Yamashita et al. demonstrated that PPARγ2 SUMOylation 
at  residue  K107,  negatively  regulating  PPARγ  transactivation  in  adipocytes,  was 
promoted by phosphorylation at S112 (170). As a possible mechanism, I interfered 
with phosphorylation at S82 by point mutation, which turned out to be not involved in 
NFκB  inhibition.  A  tentative  explanation  might  be  inherent  in  the  p38-dependent 
stabilization  and  induced  gene  expression  of  PIAS1.  TGFβ-mediated  activation  of 
Smad4 was due to SUMOylation by PIAS1, the essential SUMO E3 ligase. PIAS1 protein 
amount was increased by gene induction and protein stabilization in a p38-dependent 
manner (181). Moreover, PIAS1 can also be phosphorylated by IKKα, which in turn can 
be  activated  by  p38.  This  might  explain  the  role  of  p38  on  attenuated  NFκB 
transactivation, although it is highly speculative and needs further investigation (Figure 
6.1).  
Even though, p38 is involved in the AC-induced NFκB repression, whereas receptors 
activating p38 and initiating SUMOylation remain elusive. NFκB-inhibition was shown 
to occur in a PS-independent manner (136), thus ruling out many of the described 
recognition  receptors.  Receptors  sensing  oxLDL-like  sites  might  facilitate  PPARγ 
SUMOylation. Scavenger receptor A was recently shown to mediate p38 activation in 
dendritic cells, even though it induced a pro-inflammatory response in this system 
(182). Further investigations will be required to identify mechanisms, which facilitate 
SUMOylation of PPARγ in response to AC.  
There  is  increasing  evidence  that  PPARγ  essentially  contributes  to  a  macrophage 
phenotype shift. My data suggest that this signaling circuit operates under conditions 
when AC re-program immune functions of macrophages, exemplified by an altered 
NFκB-mediated  target  gene  expression  profile.  I  propose  that  SUMOylated  PPARg 
attenuates NFκB transactivation in response to AC by preventing NCoR co-repressor 
displacement.  My  data  reinforce  the  importance  of  PPARγ  during  resolution  of 
inflammation  and  help  to  understand  how  AC  affect  the  remarkable  plasticity  of 
macrophages associated with decreased pro-inflammatory cytokine production.  
6.2  Regulation of PPARγ during the inflammatory response 
As an anti-inflammatory mediator, the potential therapeutic role of PPARγ emerges 
not only for type-2 diabetes but also for acute and chronic inflammatory diseases (84, 
86,  88,  183).  TZDs  already  entered  phase  III  clinical  trial  for  the  treatment  of Discussion    78 
Alzheimer’s  disease  and  phase  II  trials  for  ulcerative  colitis  showing  clinical 
improvement (83, 88). Remarkably, the outcome and development of several diseases 
are accompanied with decreased PPARγ protein level. However, mechanisms impairing 
PPARγ  expression  are  ill-defined.  For  this  reason  I  elucidated  pathways  decreasing 
PPARγ expression during the onset of inflammation. 
LPS, a classical pro-inflammatory stimulus time-dependently reduced PPARγ mRNA and 
protein amounts in macrophages. In response to LPS the maximum reduction was seen 
after 6 h, which is in line with the work of Necela et al., who investigated reduction of 
PPARγ mRNA in RAW264.7 macrophages (172). Prolonged LPS exposure allowed to 
recover  mRNA  levels  to  almost  basal  value  after  24 h.  Accordingly,  treating 
macrophages with LPS for 24 h (184) or LPS and IFNγ for 15 h even provoked PPARγ 
transactivation  (185).  It  seems  likely,  that  prolonged  inflammation,  in  this  case 
prolonged stimulation with LPS, restores and activates PPARγ, helping to resolve an 
immune response by facilitating negative regulation of pro-inflammatory transcription 
factors. This late increase might be dysregulated during chronic inflammation.  
However, elucidating underlying mechanisms, Necela et al. already proposed a NFκB-
dependence  during  PPARγ  mRNA  down-regulation,  which  I  could  corroborate. 
Moreover,  pre-treatment  of  macrophages  with  rosiglitazone  also  prevented  mRNA 
decay. Interestingly, Klotz et al. observed reduced PPARγ expression in PBMCs of MS 
patients and demonstrated that pre-treatment of PBMCs from healthy individuals in 
vitro  or  long-term  oral  medication  with  pioglitazone  prior  to  PHA  prevented  PHA-
induced  PPARγ  decrease  (87),  whereas  explanations  therefore  were  left  open.  I 
suggested that restoration of PPARγ expression following agonist treatment is also due 
to abrogated NFκB activation.  
Recently, Zhou et al. observed reduced PPARγ expression in a sepsis model, which they 
contributed to increased TNFα release. Hepatic tissue and Kupffer cells from septic 
rats,  subjected  to  cecal  ligation  and  puncture  (CLP)  to  initiate  sepsis,  revealed 
attenuated PPARγ protein expression. Inhibiting LPS signaling by polymyxin B did not 
prevent  PPARγ  expression  at  20  h  after  CLP,  whereas  administration  of  TNFα 
neutralizing antibodies before the onset of sepsis prevented down-regulation of PPARγ 
in Kupffer cells (186). I assumed that a poly-microbial sepsis model initiated by CLP 
triggers  NFκB  activation  despite  blocking  LPS  signaling.  Moreover,  short  vs.  long Discussion    79 
stimulation periods might trigger different pathways contributing to PPARγ regulation. 
Exposure of primary human macrophages to TNFα for 3 h also reduced PPARγ1 mRNA 
even to a lower extent than LPS. In contrast, stimulation of macrophages with IFNγ 
slightly  induced  PPARγ1  mRNA  expression,  probably  because  of  a  missing  NFκB 
activation.  Beside  LPS  and  TNFα,  PPARγ  down-regulation  was  also  observed  upon 
TLR1/2 and 5 activation (19). I suggested that NFκB-activating inflammatory signals in 
general  such  as  oxidative  stress,  inflammatory  mediators  and  pathogens  provoke 
PPARγ  mRNA  decrease.  This hypothesis  is  supported by the  evidence  that NFκB  is 
implicated in disease conditions such as inflammatory bowel diseases or rheumatoid 
arthritis associated with impaired PPARγ expression.  
However, to further elucidate underlying mechanisms, I checked whether the PPARγ 
mRNA decrease results from an altered rate of transcription. Promoter reporter assays 
revealed a reduction of the promoter 1 activity to 60%, which seemed to be negligible, 
since promoter 1 was not induced in differentiated macrophages. Moreover, a not 
significant reduction of the promoter 3 activity after 6 h of LPS exposure unlikely would 
be  sufficient  to  explain  a  90%  decrease  of  mRNA.  Thus,  I  rather  suggested  mRNA 
destabilization as a post-transcriptional regulatory mechanism.  
Therefore,  I  determined  PPARγ  mRNA  stability  by  treating  macrophages  with  the 
transcription inhibitor DRB and noticed a reduced mRNA half-life upon LPS exposure. 
DRB  was  used,  because  actinomycin  D  affects  mRNA  stability  by  controlling  ARE-
binding proteins. Actinomycin D activated HuR by inducing its translocalization to the 
cytosol (187), which is a major regulatory step for activation of several ARE binding 
proteins, e.g. AUF1 and tristetraprolin (188-190). This might explain why Necela et al. 
observed  no  effect  of  LPS  on  mRNA  stability  when  using  actinomycin  D  to  block 
transcription  (172).  Moreover,  estimated  half-lives  can  differ  depending  on  the 
inhibitor used. Determination of the Ig κ light chain mRNA half-life varied considerably 
depending on the inhibitor, ranging from a high value of 5.9 h following DRB to a low 
value of 2.4 h following actinomycin D treatment (191). The use of 3’UTR reporter 
constructs is an established method to verify potential destabilization mechanisms (6-
8), since mRNA stability is often regulated via AU-rich 3’UTRs. Luciferase assays with a 
generated pGL3-PPARγ-3’UTR construct demonstrated the importance of the PPARγ-
3’UTR,  since  LPS  significantly  reduced  luciferase  activity.  In  silico  analysis  showed Discussion    80 
several ARE1 (AUUUA) and ARE4 (12-mer A/U, max. one mismatch) sites (9) and a 
potential miR-27a/b binding site (TargetScanHuman 5.1, http://www.targetscan.org). 
As deletion of the miR-27 site within the PPARγ-3’UTR reporter construct completely 
restored luciferase activity, I also checked miR-27a and b expression. I observed a 1.6-
fold increase of miR-27a and a nearly 2-fold increase of miR-27b in response to LPS, 
which is comparable to the induction of miR-146a after 2 h of LPS exposure in THP-1 
cells. MiR-146 is well described for its function in macrophages, where it negatively 
regulates TLR signaling (19). In addition, RNA from mouse lung extracts showed an 
increase of miR-27 a and b expression after 2-3 h of LPS exposure (192).  
Several diseases are associated with dysregulated miRNA expression. MiR-146a and 
miR-155 have been implicated in the development of rheumatoid arthritis, supposably 
by regulating components of the inflammatory response (22, 193). These miRNAs are 
induced upon NFκB transactivation (19, 20, 194). I also observed that induction of miR-
27b  was  at  least  partially  NFκB-dependent,  correlating  with  a  NFκB-dependent 
decrease of PPARγ mRNA. On account of this, I concluded that the NFκB-dependent 
PPARγ mRNA decrease results at least in part from the NFκB-dependent induction of 
miR-27b upon LPS exposure. Since transfection with  anti-miR-27b restored PPARγ1 
mRNA, a relative low induction of miR-27b upon LPS (2-fold) seems to be sufficient for 
PPARγ1  mRNA  decay.  The  impact  of  miR-27b  on  PPARγ  decay  was  proven  by 
transfecting  cells  with  a  specific  miR-27b  inhibitor,  which  partially  restored  PPARγ 
expression. PPARγ mRNA decrease mediated by miR-27 was corroborated by Lin et al. 
(195). During adipogenic differentiation of 3T3-L1 cells, microarray analysis revealed a 
reduced expression of miR-27a and b, which was associated with an increase of PPARγ 
mRNA. Moreover, transfection of cells with miR-27a and b resulted in the decay of 
PPARγ mRNA (195).  
However, taking into consideration that inhibition of miR-27b not completely restored 
PPARγ1 mRNA level, but reporter assays with the deletion construct pGL3-PPARγ-UTR-
ΔmiR-27  completely  reversed  LPS-mediated  attenuation  of  luciferase  activity,  I 
assumed additional regulatory mechanisms. I speculated that the ARE1 site (AUUUA) 
within the deleted region might as well be essential for destabilization, possibly by an 
ARE-binding protein. Several mechanisms are proposed to contribute to activation of 
ARE-binding  proteins  including  simple  gene  induction  but  also  co-translational Discussion 
degradation,  phosphorylation  and  control  of  cellular  localization  by  nucleocytosolic 
shuttling.  Inhibiting translation  with  CHX  significantly  induced PPARγ1 mRNA  levels 
under  basal  conditions,  while  showing  no  effect  on  mRNA  decay,  excluding  co
translational regulation mechanisms. Blocking exportin1
LMB  partially  reversed  PPARγ1  decrease.  On  account  of  this,  I  proposed  that  LPS 
induces  export  of  an  ARE
decay in concert with miR
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However, many autoimmune and chronic inflammatory diseases have been linked to 
impaired  PPARγ  expression.  For  example,  patients  with  MS  exhibit  enhanced 
expression  of  inflammatory  cytokines  such  as  TNFα  and  show  reduced  PPARγ 
expression  in  PBMCs  in  comparison  to  healthy  individuals  (87).  Besides  MS,  also 
patients with ulcerative colitis (196), inflammatory skin disorders (89) and Alzheimer’s 
disease (197) exhibit attenuated PPARγ expression, suggesting a link between down-
regulated PPARγ and chronic inflammatory diseases. PPARγ is well established for its 
anti-inflammatory  effects  in  attenuating  the  production  of  pro-inflammatory 
mediators.  One  might  speculate  that  decreased  PPARγ  expression  prolongs 
inflammation  and  thus  interferes  with  resolution  of  inflammation.  Therefore, 
understanding molecular mechanisms that attenuate PPARγ expression may provide 
options for new therapeutic approaches during chronic inflammation.  
6.3  Concluding remarks 
Many diseases are due to dysregulated inflammation, while an insufficient immune 
response is as detrimental as insufficient resolution. Macrophages coordinate initiation 
as well as resolution of inflammation. PPARγ is well described for its anti-inflammatory 
properties,  accounting  for  an  alternative  or  regulatory  macrophage  phenotype  in 
response to IL-4, IL-13 and also AC. Thus, dependent on environmental conditions a 
defined  regulation  of  PPARγ  is  fundamental.  My  studies  addressed  both  pro-
inflammatory as well as anti-inflammatory conditions in macrophages. Phagocytosis of 
AC is an important feature of macrophages during resolution of inflammation. I could 
show that AC provoke activation and SUMOylation of PPARγ followed by inhibition of 
NFκB  transactivation  and  concomitant  target  gene  expression.  In  contrast, 
inflammatory  conditions  provoke  a  rapid  decrease  of  PPARγ  expression,  therewith 
facilitating a proper immune response. I could demonstrate that activation of NFκB 
induces miR-27b concomitantly destabilizing PPARγ mRNA, while pre-treatment with 
TZDs prevented PPARγ decay. In conclusion, regulation of PPARγ function depends on 
the order of events. Hence, an up-coming infection down-regulates PPARγ expression 
in  a  NFκB-dependent  manner,  while  activation  of  PPARγ  before  the  onset  of 
inflammation inhibits NFκB transactivation and therewith PPARγ decay.  
Understanding  regulatory  mechanisms  of  PPARγ,  rather  during  pro-  or  anti-
inflammatory conditions might help to understand dysregulated immune responses. Discussion    83 
Especially the knowledge of mechanisms reducing PPARγ expression might provide 
options for new therapeutic approaches for chronic inflammatory diseases, since many 
have been associated with impaired PPARγ expression.  
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8  Appendix 
Buffers and solutions 
 
Buffers for cell biology 
Erythrocyte lysis buffer 
  NH4Cl  155 mM 
  KHCO3  10 mM 
  EDTA  0.1 mM 
Leukocyte running buffer 
  EDTA  2 mM 
  BSA  0.5% (w/v) 
    ® in PBS 
Leukcoyte washing buffer 
  EDTA  2 mM 
    ® in PBS 
Phosphate buffered saline (PBS) 
  NaCl   137 mM 
  KCl   2.7 mM 
  Na2HPO4   8.1 mM 
  KH2PO4   1.5 mM 
    ® Adjust pH to 7.4 
 
Buffers and solutions for protein analysis 
Blotting buffer 
  Tris-HCl   25 mM 
  Glycine   192 mM 
  Methanol  20% (v/v) 
    ® Check pH to be 8.3 
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Hypotonic cell lysis buffer 
HEPES   10 mM 
MgCl2   2 mM 
EDTA   100 μM 
KCl   10 mM 
  ® Adjust pH to 7.9 
 
Freshly added prior to use: 
  DTT   1 mM 
  PMSF   0.5 mM 
  Protease inhibitor mix  1 x 
Lower tris buffer (4 x) 
  Tris/HCl  1.5 M 
    ® Adjust pH to 8.8 
Nuclear lysis buffer 
HEPES  50 mM 
KCl   50 mM 
NaCl   300 mM 
EDTA   100 μM 
Glycerol   10% (v/v) 
  ® Adjust pH to 7.9 
 
Freshly added prior to use: 
DTT   1 mM 
PMSF   0.5 mM 
Protease inhibitor mix  1 x 
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Protein lysis buffer 
  Tris/HCl   50 mM 
  EDTA   5 mM 
  NaCl   150 mM 
  Nonidet P-40   0.5% (v/v) 
    ® Adjust pH to 8.0 
 
  Freshly added prior to use:  
  PMSF   0.5 mM 
  DTT   1 mM 
  Protease inhibitor mix   1 x 
SDS-running buffer 
  Tris/HCl  25 mM 
  Glycine  192 mM 
  SDS    0.7 mM 
    ® Adjust pH to 8.3 
SDS sample buffer (4 x) 
  Tris/HCl   125 mM 
  SDS     2% (v/v) 
  Glycerol   20% (v/v) 
  Bromophenol blue  0.002% (w/v) 
  DTT   5 mM 
    ® Adjust pH to 6.9 
 
 
 
 
 
 
 
 Appendices    99 
Sodium dodecyl sulfate (SDS)-polyacrylamide gels 
  Seperating gels  Stacking gel 
  12.5%  10%  4% 
40% Acrylamide/Bis-acrylamide 
(37.5% : 1.0% w/v) 
3 ml  2.5 ml  300 µl 
Lower tris buffer (4 x)  2.5 ml  2.5 ml   
Upper tris buffer (4 x)      750 µl 
H2O distilled  4.4 ml  4.9 ml  1.95 ml 
10% SDS  100 µl  100 µl  30 µl 
TEMED  10 µl  10 µl  2.5 µl 
10% (w/v) ammonium persulfate  100 µl  100 µl  25 µl 
 
TBS (tris buffered saline) 
  Tris/HCl   50 mM 
  NaCl   140 mM 
    ® Adjust pH to 7.4 
TTBS  
  Tween-20  0.06% (v/v) 
    ® in TBS 
Upper tris buffer (4 x) 
  Tris/HCl  0.5 M 
    ® Adjust pH to 6.8 
 
Buffers for molecular biology and microbiology  
DEPC-treated water  
1 ml Diethylpyrocarbonate (DEPC) in 1 l distilled H2O 
  ® stir overnight and autoclave 
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EMSA buffer D 
  HEPES/KOH  20 mM 
  Glycerol  20% (v/v) 
  KCl  100 mM 
  EDTA  0.5 mM 
  Nonidet P-40  0.25% (v/v) 
  DTT  2 mM 
  PMSF  0.5 mM 
    ® Adjust pH to 7.9 
EMSA buffer F 
  Ficoll  20% (v/v) 
  HEPES/KOH  100 mM 
  KCl  300 mM 
  DTT  10 mM 
  PMSF  0.5 mM 
    ® Adjust pH to 7.9 
EMSA running buffer 
Running buffer (glycerol tolerant)  
  (Purchased from Amersham Biosciences Europe GmbH, Freiburg) 
Fractionation buffer 
  Tris-HCl  20 mM 
  EDTA  2 mM 
  EGTA  5 mM 
    ® Check pH to be 7.5 
 
Freshly added prior to use: 
DTT  1 mM 
Protease inhibitor mix  1 x 
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Immunoprecipitation (IP) buffer 
  NaCl  150 mM 
  Tris/HCl (pH 8)  50 mM 
  EDTA  5 mM 
  TritonX-100  1% (v/v) 
  NP-40  0.5% (v/v) 
  Freshly added prior to use: 
  NaF  10 mM 
  PMSF  500 µM 
  Protease inhibitor mix  1 x 
SOC medium 
  Tryptone   20 g/l  
  Yeast extract  5 g/l 
  NaCl  0.5 g/l 
  MgCl2  10 mM 
  MgSO4  10 mM 
  Glucose  2 mM 
TBE (tris borate EDTA buffer) 
  Tris/HCl   90 mM 
  Boric acid  90 mM 
  EDTA   1 mM 
    ® Check pH to be 8.0 
 
Buffers for luciferase assay 
Luciferase lysis buffer 
  Tris-H3PO4  125 mM 
  DTT  10 mM 
  Triton X 100  5% 
  Glycerol   50% 
    ® Adjust pH to 7.8 Appendices    102 
Luciferase assay reagent  
  Tricine  20 mM 
  (MgCO3)4 x Mg(OH)2  x 5 H2O  1.07 mM 
  MgSO4 x 7 H2O  2.67 mM 
  EDTA-K
+  100 µM 
  DTT  33.3 mM 
  ATP  530 µM 
  Coenzyme A lithium  0.213 mg/ml 
  D-luciferine  470 mM 
    ® Check pH to be 7.8 
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